Art. -Nr.: HY-16560

Camptothecin

(Synonyms: Campathecin; (S)-(+)-Camptothecin; CPT)

70 Cited Publications

Kundenbewertung

Based on 70 publication(s) in Google Scholar

Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 7689-03-4
Formel: C₂₀H₁₆N₂O₄
Molecular Weight:348.35

Speicherung:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Camptothecin Chemical Structure

CAS. Nr.: 7689-03-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (70)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM^[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells^[2]^[3].

IC₅₀ & Target^[3]

Topoisomerase I

679 nM (IC₅₀)

Camptothecins

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Alle ADC Payloads Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
184B5	IC₅₀	4.96 μM Compound: Camptothecin	Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay	[PMID: 26602827]
1A9	ED₅₀	3.2 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human 1A9 cells by sulforhodamine B assay Cytotoxicity against human 1A9 cells by sulforhodamine B assay	[PMID: 17350834]
4T1	IC₅₀	0.17 μM Compound: 1; CPT	Antiproliferative activity against mouse 4T1 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
4T1	IC₅₀	>300 μM Compound: CPT	Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
786-0	IC₅₀	0.015 μM Compound: CPT	Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
833K	IC₅₀	10 nM Compound: CPT	Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells	10.1016/S0960-894X(97)10181-0
A 172	IC₅₀	0.14 μM Compound: CPT ((S)-Camptothecin)	Cytotoxicity against A-172 human tumor cell lines Cytotoxicity against A-172 human tumor cell lines	10.1016/0960-894X(96)00131-X
A 172	IC₅₀	0.14 μM Compound: 13 ((S)-CPT, Camptothecin)	In vitro cytotoxicity against A172 human tumor cell lines. In vitro cytotoxicity against A172 human tumor cell lines.	10.1016/0960-894X(96)00132-1
A20	IC₅₀	179.2 μM Compound: CPT	Cytostatic activity against mouse A20 cells after 24 hrs by CCK-8 assay Cytostatic activity against mouse A20 cells after 24 hrs by CCK-8 assay	[PMID: 38278140]
A2780	IC₅₀	0.004 μM Compound: camptothecin	Cytotoxicity against human A2780 cells after 72 hrs by MTS method Cytotoxicity against human A2780 cells after 72 hrs by MTS method	[PMID: 11858737]
A2780	IC₅₀	0.007 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against A2780 (human ovarian cancer) In vitro cytotoxicity against A2780 (human ovarian cancer)	[PMID: 14552770]
A2780	IC₅₀	0.07 μg/mL Compound: camptothecin	Cytotoxicity against human A2780 cells by clonogenic assay Cytotoxicity against human A2780 cells by clonogenic assay	[PMID: 16499333]
A2780	IC₅₀	0.28 μM Compound: camptothecin	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 18095653]
A2780	IC₅₀	0.2 μM Compound: 1, CPT	Cytotoxicity against human A2780 cells after 4 days by MTT assay Cytotoxicity against human A2780 cells after 4 days by MTT assay	[PMID: 18554906]
A2780	IC₅₀	0.3 μM Compound: camptothecin	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 19256478]
A2780	IC₅₀	0.28 μM Compound: Camptothecin	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 19453174]
A2780	GI₅₀	0.46 μM Compound: CPT	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
A2780	IC₅₀	0.3 μM Compound: CPT	Cytotoxicity against human A2780 cells after 4 days by MTT assay Cytotoxicity against human A2780 cells after 4 days by MTT assay	[PMID: 19702283]
A2780	IC₅₀	0.28 μM Compound: camptothecin	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 19916529]
A2780	IC₅₀	0.2 μM Compound: camptothecin	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 20961093]
A2780	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 22044245]
A2780	IC₅₀	7 nM Compound: Cpt	Cytotoxicity against human A2780 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 72 hrs by sulforhodamine B assay	[PMID: 22749423]
A2780	IC₅₀	13 nM Compound: CPT	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 24900725]
A2780	IC₅₀	0.9 μM Compound: camptothecin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 25237727]
A2780	IC₅₀	0.029 μM Compound: 1; CPT	Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay	[PMID: 27871039]
A-375	IC₅₀	0.187 μM Compound: CPT, Camptothecin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 24980118]
A-375	IC₅₀	0.013 μM Compound: Camptothecin	Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
A-375	IC₅₀	0.66 μM Compound: CPT	Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A-427	IC₅₀	24 nM Compound: CPT	Antiproliferative activity measured against A427 human lung carcinoma Antiproliferative activity measured against A427 human lung carcinoma	[PMID: 9876111]
A-431	IC₅₀	0.011 μM Compound: 1, CPT	Cytotoxicity against human A431 cells after 72 hrs by trypan blue assay Cytotoxicity against human A431 cells after 72 hrs by trypan blue assay	[PMID: 21071230]
A549	IC₅₀	330 μM Compound: C (20)(S)-1	In vitro cytotoxicity against human tumor cell line A549 In vitro cytotoxicity against human tumor cell line A549	[PMID: 10576688]
A549	IC₅₀	67 nM Compound: CPT	Cytotoxicity against A549 tumor cell line determined by WST-1 assay Cytotoxicity against A549 tumor cell line determined by WST-1 assay	[PMID: 10841808]
A549	IC₅₀	14 nM Compound: CPT	In Vitro cytotoxicity against human lung cancer cell line (A549) In Vitro cytotoxicity against human lung cancer cell line (A549)	[PMID: 11334569]
A549	IC₅₀	4 μM Compound: Camptothecin	Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form	[PMID: 11430001]
A549	IC₅₀	2.53 μM Compound: Camptothecin	In vitro antiproliferative activity of compound against AS-49 (human lung caner ) cell line was determined by SRB assay In vitro antiproliferative activity of compound against AS-49 (human lung caner ) cell line was determined by SRB assay	[PMID: 12639541]
A549	IC₅₀	0.008 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against A549 (human lung cancer) In vitro cytotoxicity against A549 (human lung cancer)	[PMID: 14552770]
A549	ED₅₀	6.9 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 17350834]
A549	IC₅₀	0.069 μM Compound: camptothecin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17498951]
A549	IC₅₀	0.004 μM Compound: camptothecin	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 17673337]
A549	IC₅₀	0.067 μM Compound: CPT, campothecin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17827007]
A549	IC₅₀	3.12 μM Compound: camptothecin	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 18095653]
A549	GI₅₀	2.8 μM Compound: 1, camptothecin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 18180162]
A549	IC₅₀	0.01 μM Compound: 1, CPT	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 18554906]
A549	IC₅₀	3.1 μM Compound: camptothecin	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 19256478]
A549	IC₅₀	0.058 μM Compound: CPT	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 19345580]
A549	IC₅₀	0.047 μM Compound: 1, CPT	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	GI₅₀	0.01 μM Compound: 1, CPT	Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
A549	IC₅₀	0.04 μM Compound: 1, CPT	Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
A549	IC₅₀	5.379 nM Compound: CPT	Cytotoxicity against human A549 cells after 48 hrs by MTT method Cytotoxicity against human A549 cells after 48 hrs by MTT method	[PMID: 20063889]
A549	GI₅₀	2.8 μM Compound: CPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20662543]
A549	IC₅₀	0.057 μM Compound: CPT	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 20942490]
A549	IC₅₀	3.6 μM Compound: camptothecin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 20961093]
A549	IC₅₀	0.03 μM Compound: Camptothecin	Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
A549	IC₅₀	0.069 μM Compound: 1, CPT	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21095131]
A549	IC₅₀	0.069 μM Compound: CPT	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21353568]
A549	GI₅₀	0.2 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21388138]
A549	IC₅₀	0.072 μg/mL Compound: CPT	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 21684168]
A549	IC₅₀	0.091 μM Compound: CPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21873069]
A549	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 22044245]
A549	IC₅₀	0.008 μM Compound: Camptothecin	Cytotoxicity against human A549 cells after 2 days by MTT assay Cytotoxicity against human A549 cells after 2 days by MTT assay	[PMID: 22325897]
A549	IC₅₀	33.8 nM Compound: 1, CPT	Cytotoxicity against human A549 after 72 hrs by SRB assay Cytotoxicity against human A549 after 72 hrs by SRB assay	[PMID: 22647222]
A549	GI₅₀	0.17 μM Compound: 1, CPT	Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
A549	IC₅₀	2.61 μM Compound: CPT	Antiproliferative activity against human A549 cells after 3 days by MTT assay Antiproliferative activity against human A549 cells after 3 days by MTT assay	[PMID: 23084702]
A549	IC₅₀	0.0158 μM Compound: 1, CPT	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23102893]
A549	GI₅₀	0.007 μM Compound: Camptothecin	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 23357037]
A549	IC₅₀	67 nM Compound: 1, CPT, NSC-100880	Cytotoxicity against human A549 cells by WST assay Cytotoxicity against human A549 cells by WST assay	[PMID: 23578545]
A549	IC₅₀	37.05 μM Compound: Camptothecin	Cytotoxicity against human A549 cells after 72 hrs ny MTT assay Cytotoxicity against human A549 cells after 72 hrs ny MTT assay	[PMID: 23974020]
A549	IC₅₀	0.65 μM Compound: 1, CPT	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24069881]
A549	IC₅₀	<0.01 μM Compound: Camptothecin	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 24180210]
A549	IC₅₀	99 nM Compound: CPT	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900725]
A549	IC₅₀	0.016 μM Compound: 1, CPT	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 25003995]
A549	IC₅₀	1.3 μM Compound: 3	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25084144]
A549	IC₅₀	1 nM Compound: camptothecin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25237727]
A549	IC₅₀	1 x 10^-3 μM Compound: camptothecin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25237727]
A549	IC₅₀	26.45 μM Compound: CPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25599951]
A549	IC₅₀	1.6 μM Compound: CPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26188908]
A549	IC₅₀	0.1 μM Compound: CPT	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26226379]
A549	IC₅₀	0.016 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 26994847]
A549	IC₅₀	1 nM Compound: Camptothecin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 27017547]
A549	IC₅₀	1 x 10^-3 μM Compound: Camptothecin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 27017547]
A549	IC₅₀	0.009 μM Compound: Camptothecin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
A549	IC₅₀	0.35 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 27156772]
A549	IC₅₀	0.12 μM Compound: Camptothecin	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 27344492]
A549	IC₅₀	0.46 μM Compound: 1; CPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27416553]
A549	IC₅₀	5.93 μM Compound: CPT	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 27721148]
A549	IC₅₀	0.006 μM Compound: 1; CPT	Antiproliferative activity against human A549 cells after 96 hrs by MTT assay Antiproliferative activity against human A549 cells after 96 hrs by MTT assay	[PMID: 27871039]
A549	IC₅₀	0.24 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28063351]
A549	IC₅₀	8.63 nM Compound: 1; CPT	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
A549	IC₅₀	0.26 μM Compound: CPT	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28351590]
A549	IC₅₀	13.64 μM Compound: Camptothecin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28462840]
A549	IC₅₀	0.7 μM Compound: Camptothecin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 28506750]
A549	IC₅₀	<1 μM Compound: CPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28511910]
A549	IC₅₀	8.87 μM Compound: Camptothecin	Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
A549	IC₅₀	5.93 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28923388]
A549	IC₅₀	8.63 nM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 28927790]
A549	IC₅₀	1 nM Compound: CPT	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 29501943]
A549	IC₅₀	1 x 10^-3 μM Compound: CPT	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 29501943]
A549	GI₅₀	0.003 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
A549	IC₅₀	5.5 μM Compound: Camptothecin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
A549	IC₅₀	2.21 μM Compound: Camptothecin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30109008]
A549	GI₅₀	0.21 μM Compound: 1	Growth inhibition of human A549 cells after 72 hrs by MTT assay Growth inhibition of human A549 cells after 72 hrs by MTT assay	[PMID: 30336023]
A549	IC₅₀	1.31 μM Compound: CPT	Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
A549	IC₅₀	0.09 μM Compound: CPT; 1	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30509782]
A549	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 30543429]
A549	IC₅₀	4.43 μM Compound: CPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30685528]
A549	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human A549 cells after 48 hrs by CCK8 assay Cytotoxicity against human A549 cells after 48 hrs by CCK8 assay	[PMID: 30702286]
A549	IC₅₀	32.11 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay	[PMID: 30853330]
A549	IC₅₀	50.88 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay	[PMID: 30853330]
A549	IC₅₀	3.32 μM Compound: Camptothecin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30902399]
A549	GI₅₀	0.099 μM Compound: CPT	Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
A549	IC₅₀	1 nM Compound: I; CPT	Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay	[PMID: 31229877]
A549	IC₅₀	1 x 10^-3 μM Compound: I; CPT	Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay	[PMID: 31229877]
A549	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
A549	IC₅₀	2.8 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
A549	IC₅₀	1 μM Compound: I; CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 32279049]
A549	IC₅₀	0.039 μM Compound: CPT	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 32292547]
A549	IC₅₀	1.56 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
A549	IC₅₀	32.1 μM Compound: Camptophecin	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33421712]
A549	IC₅₀	1 nM Compound: CPT	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 33962152]
A549	IC₅₀	1 x 10^-3 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 33962152]
A549	GI₅₀	0.31 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
A549	IC₅₀	0.17 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 34052678]
A549	IC₅₀	0.1 μM Compound: 1; CPT	Antiproliferative activity against human A549 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
A549	IC₅₀	8.9 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34852457]
A549	IC₅₀	1 nM Compound: CPT	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis	[PMID: 34952177]
A549	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
A549	IC₅₀	0.074 μM Compound: CPT	In-vitro antitumor activity against human A549 cells incubated for 72 hrs by CCK8 assay In-vitro antitumor activity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 35550978]
A549	IC₅₀	0.37 μM Compound: CPT	Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A549	IC₅₀	0.47 μM Compound: CPT	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
A549	IC₅₀	5.5 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
A549	IC₅₀	7.8 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
A549	IC₅₀	0.39 μM Compound: CPT	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
A549	IC₅₀	106.3 μM Compound: CPT	Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
A549	EC₅₀	4.17 nM Compound: 1; CPT	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38421819]
A549	GI₅₀	5.69 ng/mL Compound: 1; CPT	Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay	[PMID: 38421819]
A549	IC₅₀	0.32 ng/mL Compound: 1; CPT	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38421819]
A549	IC₅₀	0.32 nM Compound: 1; CPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38421819]
A549	IC₅₀	0.39 μM Compound: Camptothecin	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 38665827]
A549	IC₅₀	0.021 μM Compound: CPT	Cytotoxicity against human A549 cells measured after 72 hrs Cytotoxicity against human A549 cells measured after 72 hrs	[PMID: 38716896]
ADR5000 cell line	IC₅₀	0.3 μM Compound: CPT	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
ADR5000 cell line	IC₅₀	0.011 μM Compound: Camptothecin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28233677]
AGS	GI₅₀	23.76 μM Compound: 1, camptothecin	Antiproliferative activity against human AGS cells after 48 hrs by MTT assay Antiproliferative activity against human AGS cells after 48 hrs by MTT assay	[PMID: 18180162]
AGS	GI₅₀	0.01 μM Compound: 1, CPT	Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
AGS	IC₅₀	0.02 μM Compound: 1, CPT	Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
AGS	IC₅₀	23.76 μM Compound: CPT	Antiproliferative activity against human AGS cells incubated for 72 hrs by MTT assay Antiproliferative activity against human AGS cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
B16-F10	IC₅₀	2.78 μM Compound: Camptothecin	Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 24685545]
Bel-7402	IC₅₀	0.007 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against Bel7402 (human liver cancer) In vitro cytotoxicity against Bel7402 (human liver cancer)	[PMID: 14552770]
Bel-7402	IC₅₀	2.72 μg/mL Compound: 1 Camptothecin	In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay	[PMID: 15225719]
Bel-7402	IC₅₀	12.5 μM Compound: camptothecin	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 18095653]
Bel-7402	IC₅₀	0.17 μM Compound: 1, CPT	Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay	[PMID: 18554906]
Bel-7402	IC₅₀	12.5 μM Compound: camptothecin	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 19256478]
Bel-7402	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 22044245]
Bel-7402	IC₅₀	6.3 μM Compound: camptothecin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 25237727]
Bel-7402	IC₅₀	0.014 μM Compound: 1; CPT	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 27871039]
BEL-7404 tumor cell line	IC₅₀	0.14 μM Compound: CPT	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 26226379]
BEL-7404 tumor cell line	IC₅₀	0.4 μM Compound: CPT	Antiproliferative activity against human Bel7404 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Bel7404 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
BGC-823	IC₅₀	9.67 μM Compound: camptothecin	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 18095653]
BGC-823	IC₅₀	9.7 μM Compound: camptothecin	Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 19256478]
BGC-823	IC₅₀	0.21 μM Compound: camptothecin	Cytotoxicity against human BGC823 cells Cytotoxicity against human BGC823 cells	[PMID: 19916529]
BGC-823	IC₅₀	0.04 μM Compound: camptothecin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 25237727]
BGC-823	IC₅₀	1.27 μM Compound: 1; CPT	Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 27416553]
BGC-823	IC₅₀	0.057 μM Compound: 1; CPT	Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay	[PMID: 27871039]
BJ	IC₅₀	>40 μM Compound: Camp	Cytotoxicity against human BJ cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human BJ cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
BT-20	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human BT20 cells incubated for 72 hrs by SRB assay Cytotoxicity against human BT20 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
BT-20	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human BT20 cells after 3 days by SRB assay Cytotoxicity against human BT20 cells after 3 days by SRB assay	[PMID: 23142674]
BT-20	IC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human BT20 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human BT20 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 27017547]
BT-474	IC₅₀	12.75 μM Compound: CPT	Cytotoxicity against human BT474 cells after 3 days by SRB assay Cytotoxicity against human BT474 cells after 3 days by SRB assay	[PMID: 23142674]
BT-474	IC₅₀	7 μM Compound: Camptothecin	Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
BT-483	GI₅₀	1.03 μM Compound: CPT	Cytotoxicity against human BT-483 cells after 48 hrs by MTT assay Cytotoxicity against human BT-483 cells after 48 hrs by MTT assay	[PMID: 20662543]
BXPC-3	IC₅₀	0.24 μM Compound: 1, CPT	Cytotoxicity against human BXPC3 cells after 4 days by MTT assay Cytotoxicity against human BXPC3 cells after 4 days by MTT assay	[PMID: 18554906]
BXPC-3	IC₅₀	62.5 nM Compound: CPT	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth	[PMID: 37806498]
C6	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
CA46	IC₅₀	0.52 μM Compound: CPT	Cytotoxicity against human CA46 cells after 48 hrs by MTT assay Cytotoxicity against human CA46 cells after 48 hrs by MTT assay	[PMID: 26188908]
Caco-2	IC₅₀	9.55 μM Compound: Camptothecin	Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 21843907]
Caco-2	IC₅₀	0.131 μM Compound: CPT, Camptothecin	Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay	[PMID: 24980118]
CAKI-2	IC₅₀	3.96 μM Compound: Camptothecin	In vitro antiproliferative activity of compound against Caki-2 (human renal caner ) cell line was determined by SRB assay In vitro antiproliferative activity of compound against Caki-2 (human renal caner ) cell line was determined by SRB assay	[PMID: 12639541]
CAMA-1	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human CAMA1 cells incubated for 72 hrs by SRB assay Cytotoxicity against human CAMA1 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
CAMA-1	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human CAMA1 cells after 3 days by SRB assay Cytotoxicity against human CAMA1 cells after 3 days by SRB assay	[PMID: 23142674]
CAMA-1	IC₅₀	0.07 μM Compound: Camptothecin	Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition	[PMID: 38107170]
CAPAN-1	IC₅₀	0.21 μM Compound: CPT	Cytotoxicity against human Capan1 cells after 72 hrs by XTT assay Cytotoxicity against human Capan1 cells after 72 hrs by XTT assay	[PMID: 30017114]
carcinoma cell line	IC₅₀	0.33 μM Compound: CPT (Camptothecin)	Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460) Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)	[PMID: 11563925]
Ca-Ski	IC₅₀	1.8 μM Compound: Camptothecin	Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay	[PMID: 29407986]
Ca-Ski	IC₅₀	>300 μM Compound: CPT	Antiproliferative activity against human Ca-Ski cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Ca-Ski cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
CCD 19Lu	IC₅₀	2 μg/mL Compound: Camptothecin (CPT)	Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells	10.1016/S0960-894X(97)00071-1
CCRF-CEM	IC₅₀	5.3 μM Compound: Camptothecin	Cytotoxicity in human leukemic CCRF-CEM cells. Cytotoxicity in human leukemic CCRF-CEM cells.	[PMID: 14667232]
CCRF-CEM	IC₅₀	0.84 nM Compound: CPT	Inhibitory concentration against CEM cell growth after incubation in liquid medium for 72 h Inhibitory concentration against CEM cell growth after incubation in liquid medium for 72 h	[PMID: 15916431]
CCRF-CEM	IC₅₀	0.003 μM Compound: CPT	Antiproliferative activity against human CCRF-CEM cells by MTT assay Antiproliferative activity against human CCRF-CEM cells by MTT assay	[PMID: 17254669]
CCRF-CEM	GI₅₀	0.002 μM Compound: camptothecin	Growth inhibition of human CEM cells by Alamar blue assay Growth inhibition of human CEM cells by Alamar blue assay	[PMID: 17418582]
CCRF-CEM	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against p38-proficient human CCRF-CEM cells after 3 days by MTT assay Cytotoxicity against p38-proficient human CCRF-CEM cells after 3 days by MTT assay	[PMID: 19203291]
CCRF-CEM	GI₅₀	0.023 nM Compound: camptothecin	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	GI₅₀	43.21 nM Compound: camptothecin	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	CC₅₀	0.003 μM Compound: Camptothecin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 22047799]
CCRF-CEM	IC₅₀	0.005 μM Compound: CPT	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 22305342]
CCRF-CEM	CC₅₀	0.003 μM Compound: Camptothecin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 22884523]
CCRF-CEM	GI₅₀	2 nM Compound: Camptothecin	Growth inhibition of human CEM cells Growth inhibition of human CEM cells	[PMID: 23750455]
CCRF-CEM	IC₅₀	0.08 μM Compound: CPT	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
CCRF-CEM	IC₅₀	0.003 μM Compound: Camptothecin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28233677]
CCRF-CEM	GI₅₀	0.002 μM Compound: CPT	Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
CCRF-CEM	GI₅₀	0.007 μM Compound: 1	Growth inhibition of human CCRF-CEM cells after 72 hrs by MTT assay Growth inhibition of human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 30336023]
CCRF-CEM	IC₅₀	0.002 μM Compound: CPT	Cytotoxicity against human CCRF-CEM cells by MTT assay Cytotoxicity against human CCRF-CEM cells by MTT assay	[PMID: 30543429]
CCRF-CEM	IC₅₀	0.005 μg/mL Compound: Camptothecin (CPT)	Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells	10.1016/S0960-894X(97)00071-1
CCRF-SB	IC₅₀	0.003 μM Compound: CPT	Antiproliferative activity against human CCRF-SB cells by MTT assay Antiproliferative activity against human CCRF-SB cells by MTT assay	[PMID: 17254669]
CCRF-SB	CC₅₀	0.004 μM Compound: Camptothecin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 22047799]
CCRF-SB	CC₅₀	0.004 μM Compound: Camptothecin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 22884523]
CEM/C2	IC₅₀	5385 nM Compound: CPT	Inhibitory concentration against CEM/C2 cell growth after incubation in liquid medium for 72 h Inhibitory concentration against CEM/C2 cell growth after incubation in liquid medium for 72 h	[PMID: 15916431]
CEM/C2	GI₅₀	>1 μM Compound: camptothecin	Growth inhibition of topoisomerase 1 mutated CEM/C2 cells by Alamar blue assay Growth inhibition of topoisomerase 1 mutated CEM/C2 cells by Alamar blue assay	[PMID: 17418582]
CEM/C2	GI₅₀	1000 nM Compound: Camptothecin	Growth inhibition of multidrug-resistant human CEM/C2 cells Growth inhibition of multidrug-resistant human CEM/C2 cells	[PMID: 23750455]
CNE	IC₅₀	0.34 μM Compound: CPT	Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay	[PMID: 30125725]
CNE-2	IC₅₀	0.1 μM Compound: Camptothecin	Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
CNE-2	IC₅₀	0.98 μM Compound: CPT	Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay	[PMID: 30125725]
Col2	ED₅₀	57 nM Compound: camptothecin	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 15043407]
Col2	IC₅₀	0.045 μM Compound: camptothecin	Cytotoxicity against human Col2 cells by SRB assay Cytotoxicity against human Col2 cells by SRB assay	[PMID: 17498951]
Col2	IC₅₀	0.045 μM Compound: 1, CPT	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 21095131]
Col2	IC₅₀	0.045 μM Compound: CPT	Cytotoxicity against human Col2 cells by MTT assay Cytotoxicity against human Col2 cells by MTT assay	[PMID: 21353568]
COLO 201	IC₅₀	27 μM Compound: Camptothecin	Cytotoxicity against human COLO201 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay Cytotoxicity against human COLO201 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay	[PMID: 39018435]
COLO 205	IC₅₀	5.4 nM Compound: 1	Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (COLO 205) Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (COLO 205)	[PMID: 10479293]
COLO 205	IC₅₀	0.05 μM Compound: Camptothecin	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 24041234]
CRL-7065 cell line	IC₅₀	0.5 μM Compound: CPT	Antiproliferative activity against human CRL7065 cells by MTT assay Antiproliferative activity against human CRL7065 cells by MTT assay	[PMID: 17254669]
CRL-7065 cell line	CC₅₀	0.3 μM Compound: Camptothecin	Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay	[PMID: 22047799]
CRL-7065 cell line	CC₅₀	0.3 μM Compound: Camptothecin	Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay	[PMID: 22884523]
CT26	IC₅₀	34 nM Compound: camptothecin	Antiproliferative activity against mouse CT26 cell line Antiproliferative activity against mouse CT26 cell line	[PMID: 16686539]
CT26.WT	IC₅₀	0.43 μM Compound: CPT	Antiproliferative activity against mouse CT26.WT cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against mouse CT26.WT cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35868003]
Daudi	IC₅₀	118.9 μM Compound: CPT	Antiproliferative activity against human Daudi cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Daudi cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
DC3F	IC₅₀	6 nM Compound: CPT	Tested in vitro for growth inhibitory activity against DC-3F (hamster lung) cells Tested in vitro for growth inhibitory activity against DC-3F (hamster lung) cells	10.1016/S0960-894X(97)10181-0
Detroit 551	GI₅₀	0.99 μM Compound: CPT	Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay	[PMID: 20591678]
Detroit 551	GI₅₀	0.99 μM Compound: CPT	Cytotoxicity against human Detroit 551 cells after 48 hrs by MTT assay Cytotoxicity against human Detroit 551 cells after 48 hrs by MTT assay	[PMID: 20662543]
Detroit 551	IC₅₀	0.99 μM Compound: CPT	Antiproliferative activity against human Detroit 551 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human Detroit 551 cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
DLD-1	IC₅₀	14000 μM Compound: C (20)(S)-1	In vitro cytotoxicity against human tumor cell line DLD-1 In vitro cytotoxicity against human tumor cell line DLD-1	[PMID: 10576688]
DLD-1	IC₅₀	0.21 μM Compound: CPT ((S)-Camptothecin)	Cytotoxicity against DLD-1 human tumor cell lines Cytotoxicity against DLD-1 human tumor cell lines	10.1016/0960-894X(96)00131-X
DLD-1	IC₅₀	0.21 μM Compound: 13 ((S)-CPT, Camptothecin)	In vitro cytotoxicity against DLD-1 human tumor cell lines. In vitro cytotoxicity against DLD-1 human tumor cell lines.	10.1016/0960-894X(96)00132-1
DU-145	GI₅₀	0.01 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line	[PMID: 11020283]
DU-145	GI₅₀	0.01 μM Compound: 2	Growth inhibitory activity against human prostate DU-145 cell line Growth inhibitory activity against human prostate DU-145 cell line	[PMID: 15509164]
DU-145	GI₅₀	0.01 μM Compound: Camptothecin	Concentration required to inhibit the growth of human ProstateDU-145 cells Concentration required to inhibit the growth of human ProstateDU-145 cells	[PMID: 16033260]
DU-145	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human DU145 cell line Antiproliferative activity against human DU145 cell line	[PMID: 16442283]
DU-145	GI₅₀	0.01 μM Compound: 2	Antiproliferative activity against human DU145 cell line Antiproliferative activity against human DU145 cell line	[PMID: 16913702]
DU-145	IC₅₀	0.01 μM Compound: CPT	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 17254669]
DU-145	ED₅₀	10.9 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human DU145 cells by sulforhodamine B assay Cytotoxicity against human DU145 cells by sulforhodamine B assay	[PMID: 17350834]
DU-145	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17402722]
DU-145	GI₅₀	0.01 μM Compound: 1, Camptothecin	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17676830]
DU-145	GI₅₀	0.01 μM Compound: 2	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17696418]
DU-145	IC₅₀	3.2 μM Compound: camptothecin	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18178085]
DU-145	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 18630891]
DU-145	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 19783447]
DU-145	IC₅₀	1 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 19836231]
DU-145	IC₅₀	0.66 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay	[PMID: 19939682]
DU-145	IC₅₀	1.46 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 3 days Cytotoxicity against human DU145 cells after 3 days	[PMID: 19954977]
DU-145	IC₅₀	3.57 μM Compound: camptothecin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 20093033]
DU-145	GI₅₀	0.01 μM Compound: 1, CPT	Antiproliferative activity against human DU145 cells Antiproliferative activity against human DU145 cells	[PMID: 20155916]
DU-145	IC₅₀	0.94 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
DU-145	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
DU-145	IC₅₀	3.2 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 4 days by MTT assay Cytotoxicity against human DU145 cells after 4 days by MTT assay	[PMID: 20619511]
DU-145	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 20630766]
DU-145	IC₅₀	0.02 μM Compound: Camptothecin	Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
DU-145	IC₅₀	0.61 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 21115246]
DU-145	IC₅₀	0.31 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21419530]
DU-145	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21601964]
DU-145	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human DU145 cells by SRB assay Antiproliferative activity against human DU145 cells by SRB assay	[PMID: 21710981]
DU-145	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 21823606]
DU-145	CC₅₀	0.015 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 96 hrs by MTT assay Cytotoxicity against human DU145 cells after 96 hrs by MTT assay	[PMID: 22047799]
DU-145	IC₅₀	0.015 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 96 hrs Cytotoxicity against human DU145 cells after 96 hrs	[PMID: 22276775]
DU-145	IC₅₀	2.37 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 22318164]
DU-145	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
DU-145	IC₅₀	1.06 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
DU-145	IC₅₀	9.29 μM Compound: CPT	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22819942]
DU-145	CC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 96 hrs by MTT assay Cytotoxicity against human DU145 cells after 96 hrs by MTT assay	[PMID: 22884523]
DU-145	IC₅₀	0.0287 μM Compound: 1, CPT	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 23102893]
DU-145	IC₅₀	0.39 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 24013413]
DU-145	IC₅₀	0.8 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 24 to 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 to 72 hrs by MTT assay	[PMID: 24303808]
DU-145	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24502276]
DU-145	GI₅₀	18.2 nM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24502276]
DU-145	GI₅₀	0.01 μM Compound: 1	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 24800942]
DU-145	IC₅₀	4.01 μM Compound: CPT	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 24904965]
DU-145	IC₅₀	0.029 μM Compound: 1, CPT	Cytotoxicity against human DU145 cells after 72 hrs by SRB assay Cytotoxicity against human DU145 cells after 72 hrs by SRB assay	[PMID: 25003995]
DU-145	IC₅₀	0.95 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay	[PMID: 25062006]
DU-145	IC₅₀	0.11 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 25481396]
DU-145	IC₅₀	0.1 μM Compound: CPT	Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
DU-145	IC₅₀	0.02 μM Compound: camptothecin	Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
DU-145	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
DU-145	IC₅₀	0.11 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 2 days by CCK8 assay Cytotoxicity against human DU145 cells after 2 days by CCK8 assay	[PMID: 26361737]
DU-145	IC₅₀	0.02 μM Compound: Camptothecin	Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
DU-145	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human DU145 cells after 48 hrs Antiproliferative activity against human DU145 cells after 48 hrs	[PMID: 27070999]
DU-145	IC₅₀	0.11 μM Compound: Camptothecin	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
DU-145	IC₅₀	0.38 μM Compound: Camptothecin	Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
DU-145	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as growth inhibition Antiproliferative activity against human DU145 cells assessed as growth inhibition	[PMID: 28657311]
DU-145	GI₅₀	0.019 μM Compound: CPT	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
DU-145	GI₅₀	0.021 μM Compound: 1	Growth inhibition of human DU145 cells after 72 hrs by MTT assay Growth inhibition of human DU145 cells after 72 hrs by MTT assay	[PMID: 30336023]
DU-145	IC₅₀	0.016 μM Compound: CPT	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 30543429]
DU-145	GI₅₀	0.21 μM Compound: CPT	Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
DU-145	IC₅₀	0.05 μM Compound: Camptothecin	Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
DU-145	IC₅₀	1.99 μM Compound: Camptothecin	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay	[PMID: 32526552]
DU-145	IC₅₀	0.07 μM Compound: 45	Anti-proliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Anti-proliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 33143937]
DU-145	GI₅₀	0.21 μM Compound: CPT	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
DU-145	IC₅₀	0.21 μM Compound: CPT	Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
DU-145	IC₅₀	0.61 μM Compound: Camptothecin	Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis	[PMID: 37418826]
DU-145	IC₅₀	33.45 nM Compound: CPT	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth	[PMID: 37806498]
DU-145	IC₅₀	0.042 μM Compound: CPT	Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
ECa-109 cell line	IC₅₀	9.52 μM Compound: CPT	Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 27667553]
Erythrocyte	EC₅₀	429.9 μg/mL Compound: Camptothecin	Hemolytic activity in Homo sapiens (human) Erythrocyte after 30 min Hemolytic activity in Homo sapiens (human) Erythrocyte after 30 min	10.1007/s00044-010-9381-7
Fibroblast	IC₅₀	459.3 nM Compound: camptothecin	Cytotoxicity against human Fibroblasts by SRB assay Cytotoxicity against human Fibroblasts by SRB assay	[PMID: 21410162]
GLC4 cell line	IC₅₀	10 nM Compound: Cpt	Cytotoxicity against human GLC4 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human GLC4 cells after 72 hrs by sulforhodamine B assay	[PMID: 22749423]
H22	IC₅₀	0.54 μM Compound: 1; CPT	Antiproliferative activity against mouse H22 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against mouse H22 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
H69AR	IC₅₀	>300 nM Compound: 1a	Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
HBL-100	GI₅₀	0.23 μM Compound: CPT	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
HBL-100	GI₅₀	0.23 μM Compound: Camptothecin	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 23831507]
HBL-100	GI₅₀	0.2 μM Compound: Camptothecin	Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
HCC70	IC₅₀	0.044 μM Compound: Camptothecin	Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
HCCLM9	IC₅₀	>150 μM Compound: CPT	Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCT-116	GI₅₀	0.03 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line	[PMID: 11020283]
HCT-116	IC₅₀	0.009 μM Compound: camptothecin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS method Cytotoxicity against human HCT116 cells after 72 hrs by MTS method	[PMID: 11858737]
HCT-116	GI₅₀	0.03 μM Compound: 2	Growth inhibitory activity against human colon HCT116 cell line Growth inhibitory activity against human colon HCT116 cell line	[PMID: 15509164]
HCT-116	GI₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cell line Antiproliferative activity against human HCT116 cell line	[PMID: 16442283]
HCT-116	GI₅₀	0.03 μM Compound: 2	Antiproliferative activity against human HCT116 cell line Antiproliferative activity against human HCT116 cell line	[PMID: 16913702]
HCT-116	GI₅₀	0.03 μM Compound: 1	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 17402722]
HCT-116	GI₅₀	0.03 μM Compound: 1, Camptothecin	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 17676830]
HCT-116	GI₅₀	0.03 μM Compound: 2	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 17696418]
HCT-116	IC₅₀	1 μM Compound: camptothecin	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 18178085]
HCT-116	GI₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 18630891]
HCT-116	IC₅₀	2 nM Compound: camptothecin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-116	IC₅₀	0.13 μM Compound: CPT	Antiproliferative activity against human HCT116 cells after 3 days by XTT assay Antiproliferative activity against human HCT116 cells after 3 days by XTT assay	[PMID: 19691293]
HCT-116	GI₅₀	0.03 μM Compound: 1	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 19783447]
HCT-116	IC₅₀	2.77 μM Compound: Camptothecin	Cytotoxicity against human HCT116 cells after 3 days Cytotoxicity against human HCT116 cells after 3 days	[PMID: 19954977]
HCT-116	GI₅₀	0.03 μM Compound: 1, CPT	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 20155916]
HCT-116	IC₅₀	2.3 μM Compound: Camptothecin	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 20619511]
HCT-116	GI₅₀	0.03 μM Compound: 1	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 20630766]
HCT-116	IC₅₀	3.97 μM Compound: Camptothecin	Cytotoxicity against human HCT116 cells after 2 days Cytotoxicity against human HCT116 cells after 2 days	[PMID: 21419530]
HCT-116	GI₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells by SRB assay Antiproliferative activity against human HCT116 cells by SRB assay	[PMID: 21710981]
HCT-116	GI₅₀	0.03 μM Compound: 1	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 21823606]
HCT-116	GI₅₀	0.03 μM Compound: 2	Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
HCT-116	IC₅₀	<0.1 μM Compound: CPT	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 22409771]
HCT-116	IC₅₀	22.9 nM Compound: 1, CPT	Cytotoxicity against human HCT116 after 72 hrs by SRB assay Cytotoxicity against human HCT116 after 72 hrs by SRB assay	[PMID: 22647222]
HCT-116	GI₅₀	0.083 μM Compound: 1, CPT	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
HCT-116	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human HCT116 cells incubated for 72 hrs by SRB assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
HCT-116	IC₅₀	0.11 μM Compound: CPT	Antiproliferative activity against human HCT116 cells after 3 days by MTT assay Antiproliferative activity against human HCT116 cells after 3 days by MTT assay	[PMID: 23084702]
HCT-116	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human HCT116 cells after 3 days by SRB assay Cytotoxicity against human HCT116 cells after 3 days by SRB assay	[PMID: 23142674]
HCT-116	IC₅₀	0.016 μM Compound: camptothecin	Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay	[PMID: 24033077]
HCT-116	IC₅₀	0.07 μM Compound: 1, CPT	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24069881]
HCT-116	GI₅₀	0.03 μM Compound: 1	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24502276]
HCT-116	GI₅₀	17.38 nM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24502276]
HCT-116	GI₅₀	35.48 nM Compound: 1	Cytotoxicity against human HCT116 cells transfected with Top1-siRNA after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells transfected with Top1-siRNA after 72 hrs by MTT assay	[PMID: 24502276]
HCT-116	GI₅₀	0.03 μM Compound: 1	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 24800942]
HCT-116	IC₅₀	0.00015 μM Compound: CPT	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 25247770]
HCT-116	IC₅₀	0.09 μM Compound: CPT	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26226379]
HCT-116	IC₅₀	≤0.1 μM Compound: CPT	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
HCT-116	GI₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 48 hrs Antiproliferative activity against human HCT116 cells after 48 hrs	[PMID: 27070999]
HCT-116	IC₅₀	0.003 μM Compound: Camptothecin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
HCT-116	IC₅₀	0.159 μM Compound: Camptothecin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27318980]
HCT-116	IC₅₀	6.7 μM Compound: CPT	Cytotoxicity against human HCT116 cells measured after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells measured after 72 hrs by MTT assay	[PMID: 27721148]
HCT-116	IC₅₀	0.12 μM Compound: CPT	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28351590]
HCT-116	IC₅₀	0.0115 μM Compound: CPT	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28454671]
HCT-116	IC₅₀	0.159 μM Compound: Camptothecin	Antiproliferative activity against human HCT116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells measured after 48 hrs by MTT assay	[PMID: 28477443]
HCT-116	GI₅₀	0.03 μM Compound: 1	Antiproliferative activity against human HCT116 cells assessed as growth inhibition Antiproliferative activity against human HCT116 cells assessed as growth inhibition	[PMID: 28657311]
HCT-116	IC₅₀	1.88 μM Compound: CPT	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28923388]
HCT-116	GI₅₀	0.05 μM Compound: Camptothecin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
HCT-116	GI₅₀	0.195 μM Compound: Camptothecin	Antiproliferative activity against human HCT-116 p53-/- cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human HCT-116 p53-/- cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
HCT-116	GI₅₀	0.009 μM Compound: CPT	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
HCT-116	GI₅₀	0.075 μM Compound: CPT	Cytotoxicity against human HCT116 cells expressing TOP1 siRNA assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing TOP1 siRNA assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
HCT-116	GI₅₀	0.009 μM Compound: 1	Growth inhibition of human HCT116 cells after 72 hrs by MTT assay Growth inhibition of human HCT116 cells after 72 hrs by MTT assay	[PMID: 30336023]
HCT-116	GI₅₀	0.075 μM Compound: 1	Growth inhibition of human HCT116 cells expressing TOP1 siRNA after 72 hrs by MTT assay Growth inhibition of human HCT116 cells expressing TOP1 siRNA after 72 hrs by MTT assay	[PMID: 30336023]
HCT-116	IC₅₀	1.88 μM Compound: CPT	Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HCT-116	IC₅₀	0.013 μM Compound: CPT	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 30543429]
HCT-116	GI₅₀	0.009 μM Compound: CPT	Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
HCT-116	GI₅₀	0.075 μM Compound: CPT	Growth inhibition of human HCT116 cells expressing siTOP1 incubated for 72 hrs by MTT assay Growth inhibition of human HCT116 cells expressing siTOP1 incubated for 72 hrs by MTT assay	[PMID: 31176097]
HCT-116	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
HCT-116	IC₅₀	0.02 μM Compound: CPT	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
HCT-116	IC₅₀	0.009 μM Compound: CPT	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CCK8 assay	[PMID: 32292547]
HCT-116	IC₅₀	0.4 μM Compound: CPT	Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
HCT-116	IC₅₀	0.05 μM Compound: CPT	Cytotoxicity against human HCT-116 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
HCT-116	IC₅₀	8.5 nM Compound: Camptothecin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay	[PMID: 32952994]
HCT-116	IC₅₀	0.25 μM Compound: CPT	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33158579]
HCT-116	GI₅₀	0.05 μM Compound: CPT	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
HCT-116	IC₅₀	0.017 μM Compound: CPT	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 34052678]
HCT-116	IC₅₀	0.09 μM Compound: 1; CPT	Antiproliferative activity against human HCT-116 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
HCT-116	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HCT-116	IC₅₀	0.04 μM Compound: CPT	In-vitro antitumor activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay In-vitro antitumor activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay	[PMID: 35550978]
HCT-116	IC₅₀	2.01 nM Compound: Camptothecin	Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay	[PMID: 35567964]
HCT-116	IC₅₀	0.6 μM Compound: CPT	Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against human HCT-116 cells Cytotoxicity against human HCT-116 cells	[PMID: 36924947]
HCT-116	IC₅₀	0.21 μM Compound: CPT	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
HCT-116	IC₅₀	0.051 μM Compound: CPT	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
HCT-116	EC₅₀	3.15 nM Compound: 1; CPT	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38421819]
HCT-116	GI₅₀	3.86 ng/mL Compound: 1; CPT	Growth inhibition of human HCT-116 cells incubated for 72 hrs by MTT assay Growth inhibition of human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 38421819]
HCT-116	IC₅₀	2.01 ng/mL Compound: 1; CPT	Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38421819]
HCT-116	IC₅₀	2.01 nM Compound: 1; CPT	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38421819]
HCT-116	IC₅₀	0.011 μM Compound: CPT	Cytotoxicity against human HCT-116 cells measured after 72 hrs Cytotoxicity against human HCT-116 cells measured after 72 hrs	[PMID: 38716896]
HCT-116	IC₅₀	4.75 μM Compound: Camptothecin	Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells	10.1007/s00044-009-9233-5
HCT-15	IC₅₀	18 nM Compound: camptothecin	Antiproliferative activity against human HCT15 cell line Antiproliferative activity against human HCT15 cell line	[PMID: 16686539]
HCT-15	IC₅₀	0.083 μM Compound: camptothecin	Cytotoxicity against human HCT15 cells after 48 hrs Cytotoxicity against human HCT15 cells after 48 hrs	[PMID: 17673337]
HCT-15	IC₅₀	0.08 μM Compound: CPT, campothecin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 17827007]
HCT-15	IC₅₀	3 nM Compound: camptothecin	Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-15	IC₅₀	0.76 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay	[PMID: 19939682]
HCT-15	IC₅₀	0.64 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
HCT-15	IC₅₀	0.5 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HCT-15	IC₅₀	0.067 μM Compound: Camptothecin	Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
HCT-15	IC₅₀	0.8 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 21115246]
HCT-15	IC₅₀	0.5 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 21601964]
HCT-15	IC₅₀	0.096 μg/mL Compound: CPT	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 21684168]
HCT-15	IC₅₀	0.166 μM Compound: CPT	Cytotoxicity against human HCT15 cells after 48 hrs by MTT assay Cytotoxicity against human HCT15 cells after 48 hrs by MTT assay	[PMID: 21873069]
HCT-15	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 22318164]
HCT-15	IC₅₀	1.38 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HCT-15	IC₅₀	9.92 μM Compound: CPT	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22819942]
HCT-15	IC₅₀	0.42 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HCT-15	IC₅₀	10.07 μM Compound: CPT	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 24904965]
HCT-15	IC₅₀	1.98 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HCT-15	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 25481396]
HCT-15	IC₅₀	2.82 μM Compound: camptothecin	Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HCT-15	IC₅₀	0.52 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HCT-15	IC₅₀	6.08 μM Compound: CPT	Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay	[PMID: 26334499]
HCT-15	IC₅₀	0.3 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay	[PMID: 26361737]
HCT-15	IC₅₀	1.29 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay	[PMID: 26927425]
HCT-15	IC₅₀	2.82 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HCT-15	IC₅₀	7.1 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 26988802]
HCT-15	IC₅₀	0.0014 μM Compound: Camptothecin	Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HCT-15	IC₅₀	0.31 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HCT-15	IC₅₀	0.35 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
HCT-15	IC₅₀	0.6 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HCT-15	IC₅₀	0.26 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HCT-15	IC₅₀	0.76 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HCT-15	IC₅₀	0.05 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HCT-15	IC₅₀	0.02 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HCT-15	IC₅₀	0.05 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HCT-15	IC₅₀	0.049 μM Compound: Camptothecin	Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HCT-15	IC₅₀	1.59 μM Compound: Camptothecin	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay	[PMID: 32526552]
HCT-15	IC₅₀	0.08 μM Compound: CPT	Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HCT-8	IC₅₀	0.007 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against HCT-8 (human colon cancer) In vitro cytotoxicity against HCT-8 (human colon cancer)	[PMID: 14552770]
HCT-8	IC₅₀	<0.005 μg/mL Compound: 1 Camptothecin	In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay	[PMID: 15225719]
HCT-8	IC₅₀	3.15 μM Compound: camptothecin	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 18095653]
HCT-8	IC₅₀	3.2 μM Compound: camptothecin	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 19256478]
HCT-8	IC₅₀	<0.013 μM Compound: CPT	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 20392545]
HCT-8	IC₅₀	0.26 μM Compound: Camptothecin	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 22044245]
HCT-8	IC₅₀	3.6 μM Compound: camptothecin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 25237727]
HCT-8	IC₅₀	0.024 μM Compound: 1; CPT	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 27871039]
HEC-1B cell line	IC₅₀	8.64 μM Compound: Camptothecin	In vitro antiproliferative activity of compound against HEC-1-B (human endometrical caner ) cell line was determined by SRB assay In vitro antiproliferative activity of compound against HEC-1-B (human endometrical caner ) cell line was determined by SRB assay	[PMID: 12639541]
HEK293	IC₅₀	1.01 μM Compound: Camptothecin	Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HEK293	IC₅₀	7.94 μM Compound: CPT	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 22819942]
HEK293	IC₅₀	0.78 μM Compound: Camptothecin	Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HEK293	IC₅₀	0.28 μM Compound: Camptothecin	Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay	[PMID: 25062006]
HEK293	IC₅₀	0.83 μM Compound: Camptothecin	Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HEK293	IC₅₀	0.89 μM Compound: CPT	Cytotoxicity against human HEK293 cells measured after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells measured after 72 hrs by MTT assay	[PMID: 27721148]
HEK293	IC₅₀	0.01 μM Compound: Camptothecin	Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay	[PMID: 28027871]
HEK293	IC₅₀	54.69 μM Compound: Camptothecin	Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
HEK293	IC₅₀	5.6 x 10^-4 μM Compound: CPT	Antiproliferative activity against human HEK293 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEK293 cells after 48 hrs by CCK-8 assay	[PMID: 29501943]
HEK293	IC₅₀	1.61 μM Compound: CPT	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HEK293	IC₅₀	0.6 μM Compound: CPT	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32668379]
HEK293	IC₅₀	8.75 μM Compound: CPT	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hr by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hr by MTT assay	[PMID: 32682183]
HEK293	IC₅₀	5.6 nM Compound: CPT	Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis	[PMID: 34952177]
HEK293	IC₅₀	0.81 μM Compound: CPT	Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
HEK-293T	IC₅₀	5.65 μM Compound: CPT	Cytotoxicity against human HEK293T cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
HEK-293T	IC₅₀	0.69 μM Compound: CPT	Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HEK-293T	IC₅₀	0.03 μM Compound: CPT	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 36924947]
HeLa	IC₅₀	9 μM Compound: Camptothecin	Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form	[PMID: 11430001]
HeLa	GI₅₀	0.6 μM Compound: Camptothecin	Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay	[PMID: 15026047]
HeLa	IC₅₀	117.2 nM Compound: Camptothecin (table 1)	Concentration required to inhibit growth of human cervical HeLa carcinoma cell line Concentration required to inhibit growth of human cervical HeLa carcinoma cell line	[PMID: 15454230]
HeLa	GI₅₀	0.01 μM Compound: camptothecin	Growth inhibition of HeLa cells after 4 days Growth inhibition of HeLa cells after 4 days	[PMID: 17418582]
HeLa	IC₅₀	0.5 μM Compound: camptothecine	Cytotoxicity against human HeLa cells by MTT method Cytotoxicity against human HeLa cells by MTT method	[PMID: 17547457]
HeLa	IC₅₀	1.08 μM Compound: camptothecin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 18178085]
HeLa	GI₅₀	0.18 μM Compound: 1, camptothecin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18180162]
HeLa	ED₅₀	0.19 μg/mL Compound: Camptothecin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18220355]
HeLa	IC₅₀	0.19 μg/mL Compound: camptothecin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18774864]
HeLa	IC₅₀	0.072 μM Compound: CPT	Cytotoxicity against human HeLa cells by sulforhodamine B assay Cytotoxicity against human HeLa cells by sulforhodamine B assay	[PMID: 19345580]
HeLa	IC₅₀	1.22 μM Compound: camptothecin	Cytotoxicity against human HeLa cells by SRB staining-based fluorescence cytometry Cytotoxicity against human HeLa cells by SRB staining-based fluorescence cytometry	[PMID: 19653666]
HeLa	GI₅₀	1.3 μM Compound: CPT	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
HeLa	GI₅₀	0.04 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay	[PMID: 19715319]
HeLa	IC₅₀	0.2 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay	[PMID: 19715319]
HeLa	IC₅₀	0.58 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19836231]
HeLa	IC₅₀	0.63 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay	[PMID: 19939682]
HeLa	IC₅₀	1.85 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 3 days Cytotoxicity against human HeLa cells after 3 days	[PMID: 19954977]
HeLa	IC₅₀	0.86 μM Compound: camptothecin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20093033]
HeLa	IC₅₀	0.63 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum	[PMID: 20188578]
HeLa	IC₅₀	0.94 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 20356735]
HeLa	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HeLa	IC₅₀	1.1 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 20619511]
HeLa	GI₅₀	0.08 μM Compound: CPT	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20662543]
HeLa	IC₅₀	0.0089 μM Compound: 1, CPT	Cytotoxicity against human HeLa cells after 72 hrs by trypan blue assay Cytotoxicity against human HeLa cells after 72 hrs by trypan blue assay	[PMID: 21071230]
HeLa	IC₅₀	1.5 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21186067]
HeLa	GI₅₀	1.3 μM Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21388138]
HeLa	IC₅₀	1.08 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21419530]
HeLa	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21601964]
HeLa	IC₅₀	8.93 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 21983445]
HeLa	IC₅₀	1.01 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 22318164]
HeLa	IC₅₀	0.4 μM Compound: CPT	Cytotoxicity against human HeLa cells after 48 hrs by MTS assay Cytotoxicity against human HeLa cells after 48 hrs by MTS assay	[PMID: 22542106]
HeLa	IC₅₀	1.57 μM Compound: CPT	Cytotoxicity against human HeLa cells after 24 hrs by MTS assay Cytotoxicity against human HeLa cells after 24 hrs by MTS assay	[PMID: 22542106]
HeLa	IC₅₀	0.4 μM Compound: CPT	Cytotoxicity against human HeLa cells after 48 hrs by MTS assay Cytotoxicity against human HeLa cells after 48 hrs by MTS assay	[PMID: 23153813]
HeLa	IC₅₀	1.57 μM Compound: CPT	Cytotoxicity against human HeLa cells after 24 hrs by MTS assay Cytotoxicity against human HeLa cells after 24 hrs by MTS assay	[PMID: 23153813]
HeLa	GI₅₀	0.05 μM Compound: Camptothecin	Growth inhibition of human HeLa cells after 48 hrs by MTT assay Growth inhibition of human HeLa cells after 48 hrs by MTT assay	[PMID: 23357037]
HeLa	GI₅₀	0.6 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 23831507]
HeLa	IC₅₀	0.13 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 24200393]
HeLa	IC₅₀	0.5 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 24 to 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 to 72 hrs by MTT assay	[PMID: 24303808]
HeLa	IC₅₀	24 nM Compound: CPT	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900725]
HeLa	IC₅₀	0.42 μM Compound: CPT, Camptothecin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 24980118]
HeLa	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay	[PMID: 25481396]
HeLa	IC₅₀	11.62 μM Compound: CPT	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25599951]
HeLa	IC₅₀	0.18 μM Compound: camptothecin	Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HeLa	IC₅₀	0.41 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
HeLa	IC₅₀	14 μM Compound: CPT	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26188908]
HeLa	IC₅₀	1.59 μM Compound: CPT	Cytotoxicity against human HeLa cells measured after 2 days by MTT assay Cytotoxicity against human HeLa cells measured after 2 days by MTT assay	[PMID: 26334499]
HeLa	IC₅₀	6.13 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay	[PMID: 26602827]
HeLa	IC₅₀	19.8 μM Compound: CPT	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
HeLa	IC₅₀	0.59 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 3 days by CCK8 assay Cytotoxicity against human HeLa cells after 3 days by CCK8 assay	[PMID: 26927425]
HeLa	IC₅₀	0.18 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 26945111]
HeLa	IC₅₀	59.13 μM Compound: Camptothecin	Growth inhibition of human HeLa cells after 72 hrs by MTT assay Growth inhibition of human HeLa cells after 72 hrs by MTT assay	[PMID: 27344492]
HeLa	IC₅₀	1.41 μM Compound: 1; CPT	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27416553]
HeLa	IC₅₀	0.13 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
HeLa	GI₅₀	0.0054 μM Compound: CPT	Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay	[PMID: 27597409]
HeLa	IC₅₀	0.4 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HeLa	IC₅₀	11.36 μM Compound: CPT	Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 27667553]
HeLa	IC₅₀	60.01 μM Compound: CPT	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28063351]
HeLa	IC₅₀	0.09 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28068603]
HeLa	IC₅₀	0.06 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28384547]
HeLa	IC₅₀	0.12 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 28425292]
HeLa	IC₅₀	10.1 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28462840]
HeLa	IC₅₀	3.8 μM Compound: CPT	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28511910]
HeLa	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 48 hrs by WST-1 assay Cytotoxicity against human HeLa cells after 48 hrs by WST-1 assay	[PMID: 28557449]
HeLa	IC₅₀	2.62 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28633898]
HeLa	GI₅₀	0.19 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
HeLa	IC₅₀	1.37 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
HeLa	IC₅₀	0.94 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay	[PMID: 29407986]
HeLa	IC₅₀	0.13 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
HeLa	IC₅₀	1.3 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30007563]
HeLa	IC₅₀	>50 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30109008]
HeLa	IC₅₀	0.66 μM Compound: CPT	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30125725]
HeLa	IC₅₀	1.37 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
HeLa	IC₅₀	6.51 μM Compound: CPT	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30685528]
HeLa	IC₅₀	0.5 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
HeLa	IC₅₀	6 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay	[PMID: 32526552]
HeLa	IC₅₀	1.66 μM Compound: Camptothecin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 32932211]
HeLa	IC₅₀	0.23 μM Compound: CPT	Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
HeLa	IC₅₀	8.28 μM Compound: CPT	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34852457]
HeLa	GI₅₀	0.6 μM Compound: Camptothecin	Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
HeLa	IC₅₀	>300 μM Compound: CPT	Cytostatic activity against human HeLa cells after 24 hrs by CCK-8 assay Cytostatic activity against human HeLa cells after 24 hrs by CCK-8 assay	[PMID: 38278140]
HeLa	IC₅₀	8.9 ng/mL Compound: 1; CPT	Cytotoxicity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38421819]
HeLa	IC₅₀	8.9 nM Compound: 1; CPT	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 38421819]
HeLa	IC₅₀	0.108 μM Compound: CPT	Cytotoxicity against human HeLa cells measured after 72 hrs Cytotoxicity against human HeLa cells measured after 72 hrs	[PMID: 38716896]
HeLa	IC₅₀	127 μM Compound: Camptothecin	Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells	[PMID: 7699697]
HeLa	IC₅₀	0.28 μg/mL Compound: Camptothecin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-010-9381-7
HeLa	IC₅₀	0.18 μM Compound: CPT	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
Hep 3B2	GI₅₀	0.01 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay	[PMID: 19715319]
Hep 3B2	IC₅₀	0.06 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay	[PMID: 19715319]
Hep 3B2	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
Hep 3B2	IC₅₀	434.29 nM Compound: CPT	Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth	[PMID: 37806498]
Hep 3B2	IC₅₀	>300 μM Compound: CPT	Antiproliferative activity against human Hep3B cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
Hep 3B2	IC₅₀	>300 μM Compound: CPT	Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 12.5 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diph Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 12.5 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diph	[PMID: 38278140]
Hep 3B2	IC₅₀	>300 μM Compound: CPT	Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 25 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphen Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 25 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphen	[PMID: 38278140]
Hep 3B2	IC₅₀	102.9 μM Compound: CPT	Antiproliferative activity against human Hep3B cells at 2:1 compound:(2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphenyl-ethyl]amino]-1-(1H-indo Antiproliferative activity against human Hep3B cells at 2:1 compound:(2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphenyl-ethyl]amino]-1-(1H-indo	[PMID: 38278140]
HEp-2	ED₅₀	0.02 μg/mL Compound: Camptothecin	Cytotoxicity against human Hep2 cells by MTT assay Cytotoxicity against human Hep2 cells by MTT assay	[PMID: 18220355]
HEp-2	IC₅₀	0.02 μg/mL Compound: camptothecin	Cytotoxicity against human Hep2 cells by MTT assay Cytotoxicity against human Hep2 cells by MTT assay	[PMID: 18774864]
HEp-2	IC₅₀	0.7 μM Compound: Camptothecin	Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
HEp-2	IC₅₀	3.04 μM Compound: CPT	Cytotoxicity against human Hep2 cells measured after 72 hrs by MTT assay Cytotoxicity against human Hep2 cells measured after 72 hrs by MTT assay	[PMID: 27721148]
HEp-2	IC₅₀	3.04 μM Compound: CPT	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28923388]
HEp-2	IC₅₀	3.01 μM Compound: CPT	Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HepG2	IC₅₀	6.3 nM Compound: 1	Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human hepatocellular cells (HepG2) Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human hepatocellular cells (HepG2)	[PMID: 10479293]
HepG2	IC₅₀	0.03 μM Compound: CPT	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 17254669]
HepG2	IC₅₀	0.13 μM Compound: 1, CPT	Cytotoxicity against human HepG2 cells after 4 days by MTT assay Cytotoxicity against human HepG2 cells after 4 days by MTT assay	[PMID: 18554906]
HepG2	IC₅₀	0.3 μM Compound: camptothecin	Cytotoxicity against human HEPG2 cells by MTT assay Cytotoxicity against human HEPG2 cells by MTT assay	[PMID: 18841903]
HepG2	IC₅₀	455 nM Compound: camptothecin	Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay	[PMID: 19655762]
HepG2	GI₅₀	0.1 μM Compound: 1, CPT	Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
HepG2	IC₅₀	0.2 μM Compound: 1, CPT	Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
HepG2	IC₅₀	0.06 μM Compound: camptothecin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 19863101]
HepG2	CC₅₀	0.02 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 22047799]
HepG2	IC₅₀	0.02 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 96 hrs Cytotoxicity against human HepG2 cells after 96 hrs	[PMID: 22276775]
HepG2	IC₅₀	6.4 μM Compound: CPT	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22326393]
HepG2	IC₅₀	<0.1 μM Compound: CPT	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 22409771]
HepG2	GI₅₀	0.22 μM Compound: 1, CPT	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
HepG2	IC₅₀	0.01 μM Compound: CPT	Cytotoxicity against human HepG2 cells incubated for 72 hrs by SRB assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
HepG2	CC₅₀	0.04 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 22884523]
HepG2	IC₅₀	32.3 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 23562244]
HepG2	IC₅₀	0.2 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24041234]
HepG2	IC₅₀	0.6 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells after 24 to 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 to 72 hrs by MTT assay	[PMID: 24303808]
HepG2	IC₅₀	0.05 μM Compound: CPT	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24360564]
HepG2	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
HepG2	IC₅₀	29.81 μM Compound: Camptothecin	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 27344492]
HepG2	IC₅₀	1.52 μM Compound: 1; CPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27416553]
HepG2	IC₅₀	4.92 μM Compound: CPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28511910]
HepG2	IC₅₀	0.43 μM Compound: Camp	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
HepG2	IC₅₀	4.37 μM Compound: Camp	Induction of apoptosis in human HepG2 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay Induction of apoptosis in human HepG2 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay	[PMID: 29223099]
HepG2	IC₅₀	0.5 μM Compound: Camptothecin	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30007563]
HepG2	IC₅₀	13.2 μM Compound: Camptothecin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30025344]
HepG2	IC₅₀	0.37 μM Compound: CPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30055465]
HepG2	IC₅₀	1.36 μM Compound: CPT	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30125725]
HepG2	IC₅₀	6.08 μM Compound: CPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30125725]
HepG2	IC₅₀	0.66 μM Compound: CPT	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	4.79 μM Compound: CPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30685528]
HepG2	IC₅₀	5.69 μM Compound: CPT	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30875505]
HepG2	IC₅₀	0.4 μM Compound: CPT	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
HepG2	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against human HepG2 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
HepG2	IC₅₀	0.11 μM Compound: 1; CPT	Antiproliferative activity against human HepG2 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
HepG2	IC₅₀	3.5 μM Compound: CPT	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34852457]
HepG2	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HepG2	IC₅₀	0.02 μM Compound: CPT	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 36924947]
HepG2	IC₅₀	0.04 μM Compound: CPT	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
HepG2	IC₅₀	33.16 nM Compound: CPT	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth	[PMID: 37806498]
HepG2	IC₅₀	1.36 μM Compound: Camptothecin	Antiproliferative activity against human HepG2 cells assessed reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 38107170]
HepG2	IC₅₀	13.2 μM Compound: Camptothecin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay	[PMID: 38107170]
HepG2	IC₅₀	1.8 μM Compound: CPT	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HepG2	IC₅₀	7.25 ng/mL Compound: 1; CPT	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38421819]
HepG2	IC₅₀	7.25 nM Compound: 1; CPT	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 38421819]
HepG2	IC₅₀	0.09 μg/mL Compound: 1	Cytotoxicity in HepG2-T14 cancer cell line Cytotoxicity in HepG2-T14 cancer cell line	10.1016/S0960-894X(01)80158-X
HepG2	IC₅₀	0.2 μM Compound: Camptothecin	Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
HFL1	IC₅₀	1.06 μM Compound: Camptothecin	Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay	[PMID: 27643560]
HGC-27	IC₅₀	>150 μM Compound: CPT	Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HGC-27	IC₅₀	0.166 μM Compound: CPT	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35868003]
HL-60	IC₅₀	0.066 μM Compound: Camptothecin	In vitro antiproliferative activity of compound against HL-60 (human assay In vitro antiproliferative activity of compound against HL-60 (human assay	[PMID: 12639541]
HL-60	IC₅₀	130 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 15974606]
HL-60	GI₅₀	0.03 μM Compound: camptothecin	Growth inhibition of human HL60 cells by Almar blue assay Growth inhibition of human HL60 cells by Almar blue assay	[PMID: 17418582]
HL-60	IC₅₀	0.018 μM Compound: camptothecin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 17498951]
HL-60	GI₅₀	1.7 nM Compound: CPT, camptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 17962028]
HL-60	IC₅₀	0.013 μM Compound: camptothecin	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 18178085]
HL-60	IC₅₀	0.089 μM Compound: CPT	Cytotoxicity against human HL60 cells by sulforhodamine B assay Cytotoxicity against human HL60 cells by sulforhodamine B assay	[PMID: 19345580]
HL-60	IC₅₀	0.8 μM Compound: camptothecin	Cytotoxicity against human HL60 cells by rapid colorimetric assay Cytotoxicity against human HL60 cells by rapid colorimetric assay	[PMID: 19585998]
HL-60	IC₅₀	6 nM Compound: camptothecin	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 19655762]
HL-60	IC₅₀	0.067 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19836231]
HL-60	IC₅₀	0.065 μM Compound: camptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20093033]
HL-60	IC₅₀	0.59 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20356735]
HL-60	IC₅₀	0.1 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
HL-60	IC₅₀	0.017 μM Compound: 1, CPT	Cytotoxicity against human HL60 cells after 72 hrs by trypan blue assay Cytotoxicity against human HL60 cells after 72 hrs by trypan blue assay	[PMID: 21071230]
HL-60	IC₅₀	0.018 μM Compound: 1, CPT	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 21095131]
HL-60	IC₅₀	0.018 μM Compound: CPT	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 21353568]
HL-60	IC₅₀	0.065 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21419530]
HL-60	IC₅₀	0.1 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21601964]
HL-60	IC₅₀	0.6 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 2 days by MTT assay Cytotoxicity against human HL60 cells after 2 days by MTT assay	[PMID: 22325897]
HL-60	GI₅₀	<0.003 μM Compound: 1, CPT	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
HL-60	IC₅₀	0.06 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 24041234]
HL-60	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25599951]
HL-60	IC₅₀	0.015 μM Compound: CPT	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 26188908]
HL-60	IC₅₀	0.035 μM Compound: Camptothecin	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay	[PMID: 27096049]
HL-60	IC₅₀	0.019 μM Compound: Camptothecin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay	[PMID: 27318980]
HL-60	IC₅₀	0.019 μM Compound: Camptothecin	Antiproliferative activity against human HL60 cells measured after 48 hrs by WST1 assay Antiproliferative activity against human HL60 cells measured after 48 hrs by WST1 assay	[PMID: 28477443]
HL-60	IC₅₀	0.92 μM Compound: Camptothecin	Antiproliferative activity against human HL60 cells after 72 hrs by tryphan blue staining based hematocytometric method Antiproliferative activity against human HL60 cells after 72 hrs by tryphan blue staining based hematocytometric method	[PMID: 29131616]
HL-60	IC₅₀	0.02 μM Compound: Camp	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
HL-60	IC₅₀	0.07 μM Compound: Camp	Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay	[PMID: 29223099]
HL-60	IC₅₀	0.0067 μM Compound: Camptothecin	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 29429833]
HL-60	IC₅₀	0.42 μM Compound: Camptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30109008]
HL-60	IC₅₀	<0.064 μM Compound: CPT; 1	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30509782]
HL-60	IC₅₀	0.018 μM Compound: Camptothecin	Antiproliferation activity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferation activity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32201190]
HL-60	IC₅₀	1.7 μM Compound: Camptothecin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 33161122]
HL-60	IC₅₀	0.91 μM Compound: Camptothecin	Antitumor activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
HL-60	IC₅₀	0.68 μM Compound: 1	Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells	[PMID: 8410981]
HL-60	IC₅₀	5 nM Compound: CPT	Tested in vitro for growth inhibitory activity against HL60 (human promyelocytic leukemic) cells Tested in vitro for growth inhibitory activity against HL60 (human promyelocytic leukemic) cells	10.1016/S0960-894X(97)10181-0
HL60/MX2	GI₅₀	1.5 nM Compound: CPT, camptothecin	Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay	[PMID: 17962028]
HOC-21 cell line	IC₅₀	14.7 ng/mL Compound: 1a	Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay	[PMID: 7932525]
HOP-62	GI₅₀	0.01 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line	[PMID: 11020283]
HOP-62	GI₅₀	0.01 μM Compound: 2	Growth inhibitory activity against human lung HOP-62 cell line Growth inhibitory activity against human lung HOP-62 cell line	[PMID: 15509164]
HOP-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HOP62 cell line Antiproliferative activity against human HOP62 cell line	[PMID: 16442283]
HOP-62	GI₅₀	0.01 μM Compound: 2	Antiproliferative activity against human HOP62 cell line Antiproliferative activity against human HOP62 cell line	[PMID: 16913702]
HOP-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 17402722]
HOP-62	GI₅₀	0.01 μM Compound: 1, Camptothecin	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 17676830]
HOP-62	GI₅₀	0.01 μM Compound: 2	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 17696418]
HOP-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HOP62 cells Antiproliferative activity against human HOP62 cells	[PMID: 18630891]
HOP-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 19783447]
HOP-62	GI₅₀	0.01 μM Compound: 1, CPT	Antiproliferative activity against human HOP62 cells Antiproliferative activity against human HOP62 cells	[PMID: 20155916]
HOP-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 20630766]
HOP-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HOP62 cells by SRB assay Antiproliferative activity against human HOP62 cells by SRB assay	[PMID: 21710981]
HOP-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 21823606]
HOP-62	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
HOP-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human HOP62 cells by SRB assay Cytotoxicity against human HOP62 cells by SRB assay	[PMID: 24502276]
HOP-62	GI₅₀	0.01 μM Compound: 1	Growth inhibition of human HOP62 cells after 48 hrs by SRB assay Growth inhibition of human HOP62 cells after 48 hrs by SRB assay	[PMID: 24800942]
HOP-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HOP62 cells after 48 hrs Antiproliferative activity against human HOP62 cells after 48 hrs	[PMID: 27070999]
HOP-62	GI₅₀	<0.01 μM Compound: 18	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 28418653]
HOP-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HOP62 cells assessed as growth inhibition Antiproliferative activity against human HOP62 cells assessed as growth inhibition	[PMID: 28657311]
HOS	IC₅₀	0.049 μM Compound: CPT	Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
Hs 683	IC₅₀	<0.01 μM Compound: Camptothecin	Growth inhibition of human Hs683 cells after 72 hrs by MTT assay Growth inhibition of human Hs683 cells after 72 hrs by MTT assay	[PMID: 24180210]
HT-1080	IC₅₀	0.08 μM Compound: camptothecin	Cytotoxicity against human HT1080 cells by SRB assay Cytotoxicity against human HT1080 cells by SRB assay	[PMID: 17498951]
HT-1080	IC₅₀	0.08 μM Compound: 1, CPT	Cytotoxicity against human HT1080 cells Cytotoxicity against human HT1080 cells	[PMID: 21095131]
HT-1080	IC₅₀	0.08 μM Compound: CPT	Cytotoxicity against human HT1080 cells by MTT assay Cytotoxicity against human HT1080 cells by MTT assay	[PMID: 21353568]
HT-29	IC₅₀	80 nM Compound: CPT	Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay	[PMID: 10841808]
HT-29	IC₅₀	1.4 μM Compound: Camptothecin	In vitro antiproliferative activity of compound against HT-29 (human colon caner ) cell line aws determined by SRB assay In vitro antiproliferative activity of compound against HT-29 (human colon caner ) cell line aws determined by SRB assay	[PMID: 12639541]
HT-29	IC₅₀	30 nM Compound: camptothecin	Antiproliferative activity against human HT29 cell line Antiproliferative activity against human HT29 cell line	[PMID: 16686539]
HT-29	IC₅₀	0.014 μM Compound: camptothecin	Growth inhibition of human HT29 cells by neutral red assay Growth inhibition of human HT29 cells by neutral red assay	[PMID: 17204425]
HT-29	IC₅₀	3.16 μM Compound: 1, CPT	Cytotoxicity against human HT29 cells after 1 hr Cytotoxicity against human HT29 cells after 1 hr	[PMID: 18419110]
HT-29	IC₅₀	8.81 μM Compound: 1, CPT	Cytotoxicity against human mitoxantrone-resistant HT29 cells after 1 hr Cytotoxicity against human mitoxantrone-resistant HT29 cells after 1 hr	[PMID: 18419110]
HT-29	IC₅₀	3.16 μM Compound: 1, camptothecin, CPT	Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	8.81 μM Compound: 1, camptothecin, CPT	Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
HT-29	IC₅₀	0.09 μM Compound: 1, CPT	Cytotoxicity against human HT29 cells after 4 days by MTT assay Cytotoxicity against human HT29 cells after 4 days by MTT assay	[PMID: 18554906]
HT-29	IC₅₀	2 μM Compound: camptothecin	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 18841903]
HT-29	IC₅₀	0.12 μM Compound: 1, CPT	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	1.22 μM Compound: camptothecin	Cytotoxicity against human HT-29 cells by SRB staining-based fluorescence cytometry Cytotoxicity against human HT-29 cells by SRB staining-based fluorescence cytometry	[PMID: 19653666]
HT-29	GI₅₀	0.03 μM Compound: 1, CPT	Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
HT-29	IC₅₀	0.4 μM Compound: 1, CPT	Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
HT-29	IC₅₀	1.07 μM Compound: Camptothecin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19836231]
HT-29	ED₅₀	0.06 μM Compound: camptothecin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 19839614]
HT-29	IC₅₀	0.85 μM Compound: camptothecin	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20093033]
HT-29	EC₅₀	60 nM Compound: Camptothecin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 20825206]
HT-29	ED₅₀	0.06 μM Compound: Camptothecin	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 20939540]
HT-29	GI₅₀	0.05 μM Compound: Camptothecin	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 21115210]
HT-29	IC₅₀	260 nM Compound: 1a	Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
HT-29	IC₅₀	10 μM Compound: Camptothecin	Cytotoxicity against human HT-29 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 21843907]
HT-29	GI₅₀	0.05 μM Compound: Camptothecin	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23831811]
HT-29	IC₅₀	0.7 nM Compound: Camptothecin	Antiproliferative activity against human HT-29 cells by SRB assay Antiproliferative activity against human HT-29 cells by SRB assay	[PMID: 24200393]
HT-29	IC₅₀	0.06 μM Compound: CPT	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24360564]
HT-29	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
HT-29	IC₅₀	>100 μM Compound: CPT	Cytotoxicity against human HT-29 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
HT-29	IC₅₀	>150 μM Compound: CPT	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
HT-29	IC₅₀	1.37 μM Compound: CPT	Antiproliferative activity against human HT-29 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35868003]
HT-29	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 36924947]
HT-29	IC₅₀	0.19 μM Compound: CPT	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
HT-29	IC₅₀	2.35 μM Compound: CPT	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38128233]
HT-29	IC₅₀	1.87 μM Compound: CPT	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HT-29	IC₅₀	46 nM Compound: 1	Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay	[PMID: 7853331]
HT-29	IC₅₀	0.0878 μM Compound: Camptothecin	Inhibitory concentration that reduced the viability of HT 29 cell population by 50%. Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.	[PMID: 9003520]
Huh-7	IC₅₀	<0.1 μM Compound: CPT	Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay	[PMID: 22409771]
Huh-7	IC₅₀	0.15 μM Compound: CPT	Cytotoxicity against human HuH7 cells incubated for 72 hrs by SRB assay Cytotoxicity against human HuH7 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
Huh-7	IC₅₀	0.06 μM Compound: CPT	Cytotoxicity against human HuH7 cells after 3 days by SRB assay Cytotoxicity against human HuH7 cells after 3 days by SRB assay	[PMID: 23142674]
Huh-7	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay	[PMID: 25247770]
Huh-7	IC₅₀	≤0.1 μM Compound: CPT	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
Huh-7	GI₅₀	0.006 μM Compound: CPT	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
Huh-7	GI₅₀	0.099 μM Compound: 1	Growth inhibition of human HuH7 cells after 72 hrs by MTT assay Growth inhibition of human HuH7 cells after 72 hrs by MTT assay	[PMID: 30336023]
Huh-7	IC₅₀	0.0023 μM Compound: CPT	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 30543429]
Huh-7	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human HuH7 cells after 48 hrs by CCK8 assay Cytotoxicity against human HuH7 cells after 48 hrs by CCK8 assay	[PMID: 30702286]
Huh-7	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
Huh-7	IC₅₀	113.1 μM Compound: CPT	Antiproliferative activity against human Huh-7 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human Huh-7 cells incubated for 24 hrs by CCK-8 assay	[PMID: 38278140]
Huh-7	IC₅₀	0.1 μM Compound: CPT	Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation by sulforhodamine B assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation by sulforhodamine B assay	10.1039/C4MD00306C
HUVEC	ED₅₀	258 nM Compound: camptothecin	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 15043407]
HUVEC	IC₅₀	0.2 μM Compound: Camptothecin	Toxicity against HUVEC incubated for 48 hrs by MTT assay Toxicity against HUVEC incubated for 48 hrs by MTT assay	[PMID: 25590864]
HUVEC	IC₅₀	0.01 μM Compound: CPT	Cytotoxicity against human HUVEC cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
HUVEC	IC₅₀	0.012 μM Compound: CPT	In-vitro cytotoxic activity against human HUVEC cells incubated for 72 hrs by CCK8 assay In-vitro cytotoxic activity against human HUVEC cells incubated for 72 hrs by CCK8 assay	[PMID: 35550978]
HUVEC	IC₅₀	0.06 μM Compound: CPT	Cytotoxicity against HUVEC cells Cytotoxicity against HUVEC cells	[PMID: 36924947]
HUVEC	IC₅₀	0.04 μM Compound: CPT	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
IGROV-1	IC₅₀	0.012 μM Compound: 1, CPT	Cytotoxicity against human IGROV1 cells after 72 hrs Cytotoxicity against human IGROV1 cells after 72 hrs	[PMID: 18419110]
IGROV-1	IC₅₀	1.65 μM Compound: 1, CPT	Cytotoxicity against human IGROV1 cells after 1 hr Cytotoxicity against human IGROV1 cells after 1 hr	[PMID: 18419110]
IMR-32	IC₅₀	2.21 nM Compound: Camptothecin	Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors	[PMID: 12617894]
IMR-32	IC₅₀	0.08 μM Compound: Camptothecin	Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
IMR-90	IC₅₀	0.43 μM Compound: Camptothecin	Cytotoxicity against human IMR90 cells incubated for 3 days by SRB assay Cytotoxicity against human IMR90 cells incubated for 3 days by SRB assay	[PMID: 22863526]
Jurkat	IC₅₀	5.6 nM Compound: Camptothecin	Inhibitory activity against Jurkat human leukemia cells Inhibitory activity against Jurkat human leukemia cells	[PMID: 11384245]
Jurkat	IC₅₀	5.6 nM Compound: Camptothecin	Growth inhibitory activity against human Jurkat leukemia cell line (JLC) Growth inhibitory activity against human Jurkat leukemia cell line (JLC)	[PMID: 12620081]
Jurkat	IC₅₀	1.4 nM Compound: camptothecin	Growth inhibition of human Jurkat cells after 96 hrs Growth inhibition of human Jurkat cells after 96 hrs	[PMID: 18061452]
Jurkat	GI₅₀	0.09 μM Compound: 1	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 21388138]
Jurkat	IC₅₀	0.026 μM Compound: Camptothecin	Cytotoxicity against human Jurkat cells after 2 days by MTT assay Cytotoxicity against human Jurkat cells after 2 days by MTT assay	[PMID: 22325897]
Jurkat	IC₅₀	0.11 μM Compound: CPT, Camptothecin	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 24980118]
Jurkat	IC₅₀	0.085 μM Compound: CPT	Anticancer activity against human Jurkat cells after 48 hrs by MTT assay Anticancer activity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 26890120]
Jurkat	GI₅₀	0.06 μM Compound: Camptothecin	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
Jurkat	IC₅₀	22 μM Compound: CPT	Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay	[PMID: 30853330]
Jurkat	IC₅₀	51.5 μM Compound: CPT	Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay	[PMID: 30853330]
Jurkat	IC₅₀	22 μM Compound: Camptophecin	Cytotoxicity against human Jurkat cells Cytotoxicity against human Jurkat cells	[PMID: 33421712]
Jurkat	IC₅₀	0.1 μM Compound: 1; CPT	Anticancer activity against human Jurkat cells incubated for 48 hrs by MTT assay Anticancer activity against human Jurkat cells incubated for 48 hrs by MTT assay	[PMID: 34175539]
K562	IC₅₀	0.04 μM Compound: camptothecin	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
K562	IC₅₀	0.04 μM Compound: camptothecin	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	1.4 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay	[PMID: 19715319]
K562	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human K562 cells after 4 days by ELISA reader assay Cytotoxicity against human K562 cells after 4 days by ELISA reader assay	[PMID: 19939682]
K562	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum	[PMID: 20188578]
K562	IC₅₀	2 nM Compound: camptothecin	Cytotoxicity against human imitinib-resistant K562 cells by MTT assay Cytotoxicity against human imitinib-resistant K562 cells by MTT assay	[PMID: 20329739]
K562	IC₅₀	2 nM Compound: camptothecin	Cytotoxicity against imatinib-resistant human K562 cells after 72 hrs by MTT assay Cytotoxicity against imatinib-resistant human K562 cells after 72 hrs by MTT assay	[PMID: 20590148]
K562	GI₅₀	0.06 μM Compound: CPT	Cytotoxicity against human K562 cells after 72 hrs by XTT assay Cytotoxicity against human K562 cells after 72 hrs by XTT assay	[PMID: 20591678]
K562	GI₅₀	0.06 μM Compound: Camptothecin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 21115210]
K562	IC₅₀	0.59 μM Compound: Camptothecin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 21115246]
K562	IC₅₀	1.18 μM Compound: Camptothecin	Cytotoxicity against human K562 cells after 2 days Cytotoxicity against human K562 cells after 2 days	[PMID: 22318164]
K562	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human K562 cells after 24 to 72 hrs by MTT assay Cytotoxicity against human K562 cells after 24 to 72 hrs by MTT assay	[PMID: 24303808]
K562	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 24360564]
K562	IC₅₀	31 nM Compound: CPT	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 24900725]
K562	IC₅₀	0.13 μM Compound: Camptothecin	Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 25590864]
K562	IC₅₀	5.37 μM Compound: CPT	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25599951]
K562	IC₅₀	<0.003 μM Compound: CPT	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26226379]
K562	IC₅₀	0.09 μM Compound: Camp	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
K562	IC₅₀	0.711 μM Compound: Camp	Induction of apoptosis in human K562 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay Induction of apoptosis in human K562 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay	[PMID: 29223099]
K562	IC₅₀	0.07 μM Compound: CPT	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30055465]
K562	IC₅₀	<0.003 μM Compound: CPT	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
K562	IC₅₀	2.69 μM Compound: Camptothecin	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay	[PMID: 32526552]
K562	IC₅₀	0.32 μM Compound: CPT	Cytotoxicity against human K562 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
K562	IC₅₀	0.58 μM Compound: Camptothecin	Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
K562	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 36924947]
K562	IC₅₀	0.08 μM Compound: CPT	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
K562	GI₅₀	54.3 ng/mL Compound: 1; CPT	Growth inhibition of human K562 cells incubated for 72 hrs by MTT assay Growth inhibition of human K562 cells incubated for 72 hrs by MTT assay	[PMID: 38421819]
K562	IC₅₀	2 nM Compound: 1; CPT	Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 38421819]
K562	IC₅₀	57 nM Compound: CPT	Antiproliferative activity measured against K562adr leukemia cells. Antiproliferative activity measured against K562adr leukemia cells.	[PMID: 9876111]
KB	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against drug-resistant tumor cell line KBV20C. Antiproliferative activity against drug-resistant tumor cell line KBV20C.	[PMID: 10411476]
KB	IC₅₀	0.035 μM Compound: Camptothecin	Antiproliferative activity against drug-resistant tumor cell line KB7D. Antiproliferative activity against drug-resistant tumor cell line KB7D.	[PMID: 10411476]
KB	IC₅₀	0.04 μM Compound: Camptothecin	Antiproliferative activity against drug-resistant tumor cell line KBwt. Antiproliferative activity against drug-resistant tumor cell line KBwt.	[PMID: 10411476]
KB	IC₅₀	0.07 μM Compound: Camptothecin	Antiproliferative activity against drug-resistant tumor cell line KBMDR. Antiproliferative activity against drug-resistant tumor cell line KBMDR.	[PMID: 10411476]
KB	IC₅₀	1.04 μM Compound: Camptothecin	Antiproliferative activity against drug-resistant tumor cell line KBCamp. Antiproliferative activity against drug-resistant tumor cell line KBCamp.	[PMID: 10411476]
KB	EC₅₀	0.01 μg/mL Compound: camptothecin	Cytotoxicity against human KB cells after 72 hrs by MTS method Cytotoxicity against human KB cells after 72 hrs by MTS method	[PMID: 11858737]
KB	IC₅₀	28.7 nM Compound: Camptothecin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 11858760]
KB	IC₅₀	0.009 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx) In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx)	[PMID: 14552770]
KB	ED₅₀	22 nM Compound: camptothecin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15043407]
KB	IC₅₀	<0.005 μg/mL Compound: 1 Camptothecin	In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay	[PMID: 15225719]
KB	EC₅₀	0.01 μg/mL Compound: camptothecin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15270571]
KB	IC₅₀	0.02 μM Compound: CPT	Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1 Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1	[PMID: 15482929]
KB	ED₅₀	20.9 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 17350834]
KB	EC₅₀	0.0036 μM Compound: camptothecin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 17552563]
KB	IC₅₀	0.003 μM Compound: 1, CPT	Cytotoxicity against human KB cells after 4 days by MTT assay Cytotoxicity against human KB cells after 4 days by MTT assay	[PMID: 18554906]
KB	IC₅₀	1.22 μM Compound: camptothecin	Cytotoxicity against human KB cells by SRB staining-based fluorescence cytometry Cytotoxicity against human KB cells by SRB staining-based fluorescence cytometry	[PMID: 19653666]
KB	IC₅₀	38 nM Compound: camptothecin	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 19655762]
KB	IC₅₀	<0.013 μM Compound: CPT	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 20392545]
KB	IC₅₀	8.8 nM Compound: CPT	Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay	[PMID: 22698783]
KB	IC₅₀	0.121 μM Compound: 1, CPT	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 23102893]
KB	IC₅₀	0.02 μM Compound: Camptothecin	Antiproliferative activity against human KB cells by SRB assay Antiproliferative activity against human KB cells by SRB assay	[PMID: 24200393]
KB	IC₅₀	0.037 μM Compound: 1, CPT	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 25003995]
KB	IC₅₀	0.037 μM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 26994847]
KB	IC₅₀	50 nM Compound: 1; CPT	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
KB	IC₅₀	50 nM Compound: 1	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 28927790]
KB	ED₅₀	2.3 μg/mL Compound: Camptothecin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7130986]
KB	IC₅₀	0.01 μg/mL Compound: Camptothecin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8759170]
KB	IC₅₀	0.008 μM Compound: Camptothecin	Inhibitory concentration that reduced the viability of KB cell population by 50%. Inhibitory concentration that reduced the viability of KB cell population by 50%.	[PMID: 9003520]
KB	CC₅₀	0.006 μM Compound: Camptothecin	Compound concentration required to reduce the exponential growth of KB cells by 50% Compound concentration required to reduce the exponential growth of KB cells by 50%	[PMID: 9767632]
KB	IC₅₀	0.01 μg/mL Compound: 1	Cytotoxicity in KB cancer cell line Cytotoxicity in KB cancer cell line	10.1016/S0960-894X(01)80158-X
KB	IC₅₀	0.04 μg/mL Compound: 1	Cytotoxicity in KB VP-16 R cancer cell line Cytotoxicity in KB VP-16 R cancer cell line	10.1016/S0960-894X(01)80158-X
KB 3-1	IC₅₀	0.01 μM Compound: CPT	Concentration required to inhibit cell proliferation in KB3-1 tumor cell line Concentration required to inhibit cell proliferation in KB3-1 tumor cell line	[PMID: 15482929]
KB 3-1	IC₅₀	0.02 μM Compound: CPT	Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP	[PMID: 15482929]
KB 3-1	IC₅₀	0.015 μM Compound: CPT	Cytotoxicity against human KB3-1 cells after 4 days by MTT assay Cytotoxicity against human KB3-1 cells after 4 days by MTT assay	[PMID: 18676151]
KB 3-1	IC₅₀	0.015 μM Compound: CPT	Cytotoxicity against human KB3-1 cells by MTT method Cytotoxicity against human KB3-1 cells by MTT method	[PMID: 18771930]
KB VCR R	IC₅₀	0.009 μM Compound: 1 (Camptothecin)	In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line) In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line)	[PMID: 14552770]
KB VCR R	IC₅₀	0.03 μg/mL Compound: 1	Cytotoxicity in KB VCR R cancer cell line Cytotoxicity in KB VCR R cancer cell line	10.1016/S0960-894X(01)80158-X
KB-V1	IC₅₀	0.025 μM Compound: CPT	Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay	[PMID: 18676151]
KB-V1	IC₅₀	0.025 μM Compound: CPT	Cytotoxicity against human KBV1 cells by MTT method Cytotoxicity against human KBV1 cells by MTT method	[PMID: 18771930]
KG-1	IC₅₀	1.6 μM Compound: Camptothecin	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 33161122]
KG-1	IC₅₀	2.31 μM Compound: Camptothecin	Antitumor activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
L02	IC₅₀	2.15 μM Compound: CPT	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30875505]
L02	IC₅₀	>150 μM Compound: CPT	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
L02	IC₅₀	0.14 μM Compound: CPT	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
L02	IC₅₀	0.59 μM Compound: CPT	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
L1210	IC₅₀	0.03 μM Compound: Camptothecin	Inhibitory concentration required against L1210 leukemia cells Inhibitory concentration required against L1210 leukemia cells	[PMID: 12182872]
L1210	IC₅₀	0.33 μM Compound: CPT	Inhibitory concentration against L1210 leukemia cell proliferation Inhibitory concentration against L1210 leukemia cell proliferation	[PMID: 12873503]
L1210	IC₅₀	0.06 μM Compound: CPT	In vitro cytotoxic activity of compound against mouse leukemia L1210 cell line In vitro cytotoxic activity of compound against mouse leukemia L1210 cell line	[PMID: 15081041]
L1210	IC₅₀	23 nM Compound: 1 (Camptothecin)	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
L1210	IC₅₀	0.03 μM Compound: 1, CPT, NSC-100880	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 23578545]
L1210	IC₅₀	510 nM Compound: CPT	Cytotoxicity against mouse L1210 cells overexpressing folate receptor assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells overexpressing folate receptor assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24901491]
L1210	IC₅₀	0.014 μM Compound: 1	Concentration that inhibits the proliferation of L1210 cells by 50% Concentration that inhibits the proliferation of L1210 cells by 50%	[PMID: 2537428]
L1210	IC₅₀	14 nM Compound: 1; CPT	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 38421819]
L1210	ED₅₀	2.8 x 10^-6 mM Compound: 1, Camptothecin	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 423214]
L1210	IC₅₀	0.015 μM Compound: Camptothecin	Cytotoxicity was measured on cultured murine lymphoblastic leukemia cells (L1210) Cytotoxicity was measured on cultured murine lymphoblastic leukemia cells (L1210)	[PMID: 8246238]
L1210	IC₅₀	0.18 μM Compound: CPT ((S)-Camptothecin)	Cytotoxicity against L1210 tumor cell lines in mice Cytotoxicity against L1210 tumor cell lines in mice	10.1016/0960-894X(96)00131-X
L1210	IC₅₀	0.18 μM Compound: 13 ((S)-CPT, Camptothecin)	In vitro cytotoxicity against L1210 mouse leukemia tumor cell line. In vitro cytotoxicity against L1210 mouse leukemia tumor cell line.	10.1016/0960-894X(96)00132-1
L1210	IC₅₀	126 nM Compound: CPT	Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells	10.1016/S0960-894X(97)00398-3
L2987	IC₅₀	0.4 μM Compound: 1 (CPT)	Compound was evaluated for antigen specific activity in vitro L2987 cell line Compound was evaluated for antigen specific activity in vitro L2987 cell line	[PMID: 11755358]
L929	IC₅₀	1.132 μM Compound: CPT	Cytotoxicity against mouse L929 cells measured after 72 hrs Cytotoxicity against mouse L929 cells measured after 72 hrs	[PMID: 38716896]
LN-229	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human LN229 cells after 48 hrs by CCK8 assay Cytotoxicity against human LN229 cells after 48 hrs by CCK8 assay	[PMID: 30702286]
LNCaP	IC₅₀	86.1 nM Compound: Camptothecin	Cytotoxicity against human LNCAP cells by MTT assay Cytotoxicity against human LNCAP cells by MTT assay	[PMID: 11858760]
LNCaP	ED₅₀	28 nM Compound: camptothecin	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15043407]
LNCaP	ED₅₀	2 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human LNCAP cells by sulforhodamine B assay Cytotoxicity against human LNCAP cells by sulforhodamine B assay	[PMID: 17350834]
LNCaP	ED₅₀	>10 μM Compound: Camptothecin	Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
LoVo	IC₅₀	3.1 μM Compound: CPT	Cytotoxicity against human LoVo cells after 3 days by MTT assay Cytotoxicity against human LoVo cells after 3 days by MTT assay	[PMID: 20942490]
LoVo	GI₅₀	0.008 μM Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21388138]
LoVo	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human LoVo cells after 48 hrs by CCK8 assay Cytotoxicity against human LoVo cells after 48 hrs by CCK8 assay	[PMID: 30702286]
LoVo	IC₅₀	1.54 μM Compound: 1; CPT	Antiproliferative activity against human LoVo cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
LOX IMVI	IC₅₀	48 nM Compound: 1	Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay	[PMID: 7853331]
Lu1	IC₅₀	28.7 nM Compound: Camptothecin	Cytotoxicity against human Lu1 cells by MTT assay Cytotoxicity against human Lu1 cells by MTT assay	[PMID: 11858760]
Lu1	ED₅₀	29 nM Compound: camptothecin	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15043407]
Lu1	ED₅₀	>10 μM Compound: Camptothecin	Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
LX-1	IC₅₀	0.12 μM Compound: camptothecin	Cytotoxicity against human LX1 cells after 72 hrs by MTS method Cytotoxicity against human LX1 cells after 72 hrs by MTS method	[PMID: 11858737]
M059J	IC₅₀	5.5 μM Compound: CPT	Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
Macrophage	IC₅₀	0.62 μM Compound: CPT	Cytotoxicity against BALB/C mouse macrophages Cytotoxicity against BALB/C mouse macrophages	[PMID: 22932312]
Macrophage	EC₅₀	18.32 μM Compound: CPT	Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs infection by propidium iodide staining analysis relative to control Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs infection by propidium iodide staining analysis relative to control	[PMID: 36823782]
Mahlavu	IC₅₀	<0.1 μM Compound: CPT	Cytotoxicity against human Mahlavu cells after 72 hrs by SRB assay Cytotoxicity against human Mahlavu cells after 72 hrs by SRB assay	[PMID: 22409771]
Mahlavu	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
MCF10	IC₅₀	24.77 μM Compound: Camptothecin	Cytotoxicity against human MCF10 cells assessed as reduction in cell viability after 3 hrs by MTT assay Cytotoxicity against human MCF10 cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 33962153]
MCF-10A	IC₅₀	0.27 μM Compound: CPT	Cytotoxicity against human MCF10A cells after 2 days Cytotoxicity against human MCF10A cells after 2 days	[PMID: 24904965]
MCF-10A	IC₅₀	0.97 μM Compound: Camptothecin	Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay	[PMID: 26361737]
MCF-10A	IC₅₀	2.19 μM Compound: 1; CPT	Antiproliferative activity against human MCF-10A cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
MCF-10A	IC₅₀	2.58 μM Compound: CPT	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36351049]
MCF-10A	IC₅₀	3.02 μM Compound: CPT	Cytotoxicity against HER-negative human MCF-10A cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against HER-negative human MCF-10A cells incubated for 48 hrs by CCK-8 assay	[PMID: 38104378]
MCF-12A	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human MCF12A cells after 3 days by SRB assay Cytotoxicity against human MCF12A cells after 3 days by SRB assay	[PMID: 23142674]
MCF7	IC₅₀	0.32 μM Compound: CPT	In vitro cytotoxic activity of compound against human MCF-7 cell line In vitro cytotoxic activity of compound against human MCF-7 cell line	[PMID: 15081041]
MCF7	EC₅₀	0.072 μM Compound: camptothecin	Cytotoxicity against human MCF7 after 3 days by SRB assay Cytotoxicity against human MCF7 after 3 days by SRB assay	[PMID: 15730238]
MCF7	IC₅₀	0.04 μM Compound: CPT	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 17254669]
MCF7	ED₅₀	3.2 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human MCF7 cells by sulforhodamine B assay Cytotoxicity against human MCF7 cells by sulforhodamine B assay	[PMID: 17350834]
MCF7	GI₅₀	0.01 μM Compound: camptothecin	Growth inhibition of adriamycin-resistant MCF7 cells after 4 days Growth inhibition of adriamycin-resistant MCF7 cells after 4 days	[PMID: 17418582]
MCF7	GI₅₀	0.01 μM Compound: camptothecin	Growth inhibition of MCF7 cells after 4 days Growth inhibition of MCF7 cells after 4 days	[PMID: 17418582]
MCF7	IC₅₀	0.2 μM Compound: 1, CPT	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 18554906]
MCF7	IC₅₀	10 μM Compound: camptothecin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18841903]
MCF7	ED₅₀	>10 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay	[PMID: 19026551]
MCF7	IC₅₀	1.22 μM Compound: camptothecin	Cytotoxicity against human MCF7 cells by SRB staining-based fluorescence cytometry Cytotoxicity against human MCF7 cells by SRB staining-based fluorescence cytometry	[PMID: 19653666]
MCF7	IC₅₀	10 nM Compound: camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 19655762]
MCF7	IC₅₀	3 nM Compound: camptothecin	Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay	[PMID: 19655762]
MCF7	GI₅₀	0.01 μM Compound: 1, CPT	Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
MCF7	IC₅₀	1.1 μM Compound: 1, CPT	Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay	[PMID: 19715319]
MCF7	IC₅₀	0.06 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay	[PMID: 19939682]
MCF7	IC₅₀	7.42 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 3 days Cytotoxicity against human MCF7 cells after 3 days	[PMID: 19954977]
MCF7	IC₅₀	0.02 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 20392545]
MCF7	GI₅₀	0.28 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by SRB assay	[PMID: 20438092]
MCF7	GI₅₀	0.57 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay	[PMID: 20591678]
MCF7	IC₅₀	14.2 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 20619511]
MCF7	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 20630766]
MCF7	GI₅₀	0.01 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21115210]
MCF7	IC₅₀	2.43 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21115246]
MCF7	IC₅₀	0.65 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21186067]
MCF7	GI₅₀	6 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21388138]
MCF7	IC₅₀	1.6 nM Compound: camptothecin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 21410162]
MCF7	IC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 21513293]
MCF7	IC₅₀	11.12 μM Compound: 4	Anticancer activity against human MCF7 cells Anticancer activity against human MCF7 cells	[PMID: 21599000]
MCF7	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 21710981]
MCF7	GI₅₀	0.013 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21823606]
MCF7	IC₅₀	0.056 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 21978950]
MCF7	CC₅₀	0.02 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 22047799]
MCF7	IC₅₀	1.8 μM Compound: camptothecin	Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay	[PMID: 22197145]
MCF7	IC₅₀	2.6 μM Compound: camptothecin	Cytotoxicity against human MCF7 cells by WST-1 assay Cytotoxicity against human MCF7 cells by WST-1 assay	[PMID: 22197145]
MCF7	IC₅₀	3.91 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 2 days Cytotoxicity against human MCF7 cells after 2 days	[PMID: 22318164]
MCF7	GI₅₀	0.013 μM Compound: 2	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
MCF7	IC₅₀	1.6 nM Compound: Camptothecin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 22376176]
MCF7	IC₅₀	<0.1 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 22409771]
MCF7	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells incubated for 3 days by SRB assay Cytotoxicity against human MCF7 cells incubated for 3 days by SRB assay	[PMID: 22863526]
MCF7	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
MCF7	CC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 22884523]
MCF7	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 23142674]
MCF7	GI₅₀	0.002 μM Compound: Camptothecin	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 23357037]
MCF7	GI₅₀	0.01 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23831811]
MCF7	IC₅₀	<0.01 μM Compound: Camptothecin	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 24180210]
MCF7	IC₅₀	3.3 nM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 24200393]
MCF7	GI₅₀	0.013 μM Compound: 1	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 24502276]
MCF7	GI₅₀	0.01 μM Compound: 1	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 24800942]
MCF7	IC₅₀	26 nM Compound: CPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24900725]
MCF7	IC₅₀	65.1 nM Compound: CPT	Cytotoxicity against human MCF7 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24901491]
MCF7	IC₅₀	<0.024 μg/mL Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 24940955]
MCF7	IC₅₀	0.0005 μM Compound: 3	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 25084144]
MCF7	IC₅₀	0.003 μM Compound: 3	Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay	[PMID: 25084144]
MCF7	IC₅₀	0.0006 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 25247770]
MCF7	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay	[PMID: 25481396]
MCF7	IC₅₀	6 μM Compound: CPT	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
MCF7	IC₅₀	≤0.1 μM Compound: CPT	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
MCF7	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 48 hrs Antiproliferative activity against human MCF7 cells after 48 hrs	[PMID: 27070999]
MCF7	IC₅₀	4.54 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
MCF7	IC₅₀	<0.0018 μM Compound: Camptothecin	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	<0.0018 μM Compound: Camptothecin	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	<0.0018 μM Compound: Camptothecin	Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 28006904]
MCF7	IC₅₀	71.3 μM Compound: CPT	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28063351]
MCF7	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells by SRB assay Antiproliferative activity against human MCF7 cells by SRB assay	[PMID: 28274626]
MCF7	IC₅₀	87.5 nM Compound: 1; CPT	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MCF7	IC₅₀	0.073 μM Compound: Camptothecin	Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay	[PMID: 28409637]
MCF7	GI₅₀	0.013 μM Compound: 18	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 28418653]
MCF7	IC₅₀	28.66 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28462840]
MCF7	GI₅₀	0.013 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as growth inhibition Antiproliferative activity against human MCF7 cells assessed as growth inhibition	[PMID: 28657311]
MCF7	IC₅₀	13.62 μM Compound: Camptothecin	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
MCF7	IC₅₀	87.5 nM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 28927790]
MCF7	IC₅₀	0.34 μM Compound: Camp	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
MCF7	GI₅₀	0.06 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
MCF7	IC₅₀	160 nM Compound: Camptothecin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29541373]
MCF7	IC₅₀	0.42 μM Compound: CPT	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30125725]
MCF7	IC₅₀	0.04 μM Compound: CPT	Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
MCF7	IC₅₀	0.68 μM Compound: CPT; 1	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30509782]
MCF7	IC₅₀	0.68 μM Compound: CPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	2.5 μM Compound: CPT	Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis	[PMID: 30897325]
MCF7	GI₅₀	0.012 μM Compound: CPT	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
MCF7	IC₅₀	0.03 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31546197]
MCF7	IC₅₀	0.084 μM Compound: CPT	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay	[PMID: 32292547]
MCF7	IC₅₀	2.8 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay	[PMID: 32526552]
MCF7	IC₅₀	2.5 μM Compound: CPT	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hr by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hr by MTT assay	[PMID: 32682183]
MCF7	IC₅₀	1.67 μM Compound: CPT	Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
MCF7	GI₅₀	0.35 μM Compound: CPT	Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
MCF7	GI₅₀	3.21 μM Compound: CPT	Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 34008967]
MCF7	IC₅₀	0.56 μM Compound: 1; CPT	Antiproliferative activity against human MCF7 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
MCF7	IC₅₀	0.021 μM Compound: CPT	In-vitro antitumor activity against human MCF7 cells incubated for 72 hrs by CCK8 assay In-vitro antitumor activity against human MCF7 cells incubated for 72 hrs by CCK8 assay	[PMID: 35550978]
MCF7	IC₅₀	0.35 μM Compound: CPT	Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MCF7	IC₅₀	18.6 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MCF7	IC₅₀	6.39 μM Compound: CPT	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
MCF7	IC₅₀	<0.01 μM Compound: Camptothecin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by SRB assay	[PMID: 38107170]
MCF7	IC₅₀	6.85 μM Compound: CPT	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MCF7	IC₅₀	0.324 μM Compound: CPT	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
MCF7	GI₅₀	1.98 ng/mL Compound: 1; CPT	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 38421819]
MCF7	IC₅₀	3.1 nM Compound: 1; CPT	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38421819]
MCF7	IC₅₀	3.1 nM Compound: CPT	Antiproliferative activity measured against MCF-7-mdr cells. Antiproliferative activity measured against MCF-7-mdr cells.	[PMID: 9876111]
MCF7	IC₅₀	0.02 μg/mL Compound: 1	Cytotoxicity in MCF-7 cancer cell line Cytotoxicity in MCF-7 cancer cell line	10.1016/S0960-894X(01)80158-X
MDA-MB-157	IC₅₀	0.02 μM Compound: CPT	Cytotoxicity against human MDA-MB-157 cells after 3 days by SRB assay Cytotoxicity against human MDA-MB-157 cells after 3 days by SRB assay	[PMID: 23142674]
MDA-MB-231	IC₅₀	0.291 μM Compound: camptothecin	Growth inhibition of human MDA-MB-231 cells by neutral red assay Growth inhibition of human MDA-MB-231 cells by neutral red assay	[PMID: 17204425]
MDA-MB-231	IC₅₀	4.16 μM Compound: camptothecin	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 18178085]
MDA-MB-231	IC₅₀	0.68 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 19836231]
MDA-MB-231	IC₅₀	1.1 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 3 days Cytotoxicity against human MDA-MB-231 cells after 3 days	[PMID: 19954977]
MDA-MB-231	IC₅₀	0.92 μM Compound: camptothecin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20093033]
MDA-MB-231	IC₅₀	0.3 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system	[PMID: 20392646]
MDA-MB-231	GI₅₀	1.3 μM Compound: Camptothecin	Antiproliferative activity against estrogen receptor deficient human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against estrogen receptor deficient human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 20438092]
MDA-MB-231	IC₅₀	4.2 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay	[PMID: 20619511]
MDA-MB-231	IC₅₀	0.33 μM Compound: CPT	Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay	[PMID: 21044847]
MDA-MB-231	IC₅₀	0.97 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 2 days Cytotoxicity against human MDA-MB-231 cells after 2 days	[PMID: 21419530]
MDA-MB-231	IC₅₀	2.7 μM Compound: camptothecin	Cytotoxicity against human MDA-MB-231 cells by WST-1 assay Cytotoxicity against human MDA-MB-231 cells by WST-1 assay	[PMID: 22197145]
MDA-MB-231	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human MDA-MB-231 cells after 3 days by SRB assay Cytotoxicity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 23142674]
MDA-MB-231	IC₅₀	162 nM Compound: CPT	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24900725]
MDA-MB-231	IC₅₀	0.342 μM Compound: CPT, Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24980118]
MDA-MB-231	IC₅₀	5.77 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 26602827]
MDA-MB-231	IC₅₀	8.83 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MDA-MB-231	IC₅₀	307 nM Compound: 1; CPT	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 28285912]
MDA-MB-231	IC₅₀	307 nM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28927790]
MDA-MB-231	GI₅₀	0.4 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
MDA-MB-231	IC₅₀	540 nM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29541373]
MDA-MB-231	IC₅₀	16.44 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30109008]
MDA-MB-231	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human MDA231 cells after 48 hrs by CCK8 assay Cytotoxicity against human MDA231 cells after 48 hrs by CCK8 assay	[PMID: 30702286]
MDA-MB-231	IC₅₀	23.98 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-231	IC₅₀	28.4 nM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay	[PMID: 32952994]
MDA-MB-231	IC₅₀	0.241 μM Compound: CPT	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 34052678]
MDA-MB-231	IC₅₀	0.17 μM Compound: CPT	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MDA-MB-231	IC₅₀	>6.4 μM Compound: 1; CPT	Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Top1 assessed as cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Top1 assessed as cell viability by MTT assay	[PMID: 34844412]
MDA-MB-231	IC₅₀	0.42 μM Compound: 1; CPT	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
MDA-MB-231	IC₅₀	264 nM Compound: 1; CPT	Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Ctrl assessed as cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Ctrl assessed as cell viability by MTT assay	[PMID: 34844412]
MDA-MB-231	IC₅₀	0.49 μM Compound: CPT	Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MDA-MB-231	IC₅₀	1.06 μM Compound: CPT	Cytotoxicity against HER-negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against HER-negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36351049]
MDA-MB-231	IC₅₀	>100 μM Compound: CPT	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 36924947]
MDA-MB-231	IC₅₀	>100 μM Compound: CPT	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
MDA-MB-231	IC₅₀	0.53 μM Compound: CPT	Cytotoxicity against HER-negative human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against HER-negative human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38104378]
MDA-MB-231	IC₅₀	<0.01 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 38107170]
MDA-MB-231	IC₅₀	0.62 μM Compound: CPT	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MDA-MB-231	IC₅₀	0.108 μM Compound: CPT	Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
MDA-MB-231	IC₅₀	2.11 μM Compound: CPT	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
MDA-MB-361	IC₅₀	0.17 μM Compound: CPT	Cytotoxicity against human MDA-MB-361 cells after 3 days by SRB assay Cytotoxicity against human MDA-MB-361 cells after 3 days by SRB assay	[PMID: 23142674]
MDA-MB-361	IC₅₀	0.17 μM Compound: Camptothecin	Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition	[PMID: 38107170]
MDA-MB-435	GI₅₀	0.04 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line	[PMID: 11020283]
MDA-MB-435	IC₅₀	15 nM Compound: camptothecin	Inhibition against MDA-MB-435 human breast cancer cells in the absence of HSA Inhibition against MDA-MB-435 human breast cancer cells in the absence of HSA	[PMID: 11052802]
MDA-MB-435	IC₅₀	375 nM Compound: camptothecin	Inhibition against MDA-MB-435 human breast cancer cells in the presence of 11 mg/mL HSA Inhibition against MDA-MB-435 human breast cancer cells in the presence of 11 mg/mL HSA	[PMID: 11052802]
MDA-MB-435	GI₅₀	0.04 μM Compound: 2	Growth inhibitory activity against human breast MDA-MB-435 cell line Growth inhibitory activity against human breast MDA-MB-435 cell line	[PMID: 15509164]
MDA-MB-435	GI₅₀	0.04 μM Compound: Camptothecin	Concentration required to inhibit the growth of human Breast MDA-MB-435 cells Concentration required to inhibit the growth of human Breast MDA-MB-435 cells	[PMID: 16033260]
MDA-MB-435	GI₅₀	0.04 μM Compound: 1	Antiproliferative activity against human MDA-MB-435 cell line Antiproliferative activity against human MDA-MB-435 cell line	[PMID: 16442283]
MDA-MB-435	GI₅₀	0.04 μM Compound: 2	Antiproliferative activity against human MDA-MB-435 cell line Antiproliferative activity against human MDA-MB-435 cell line	[PMID: 16913702]
MDA-MB-435	GI₅₀	0.04 μM Compound: 1, Camptothecin	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 17676830]
MDA-MB-435	GI₅₀	0.04 μM Compound: 2	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 17696418]
MDA-MB-435	GI₅₀	0.04 μM Compound: 1	Antiproliferative activity against human MDA-MB-435 cells Antiproliferative activity against human MDA-MB-435 cells	[PMID: 18630891]
MDA-MB-435	GI₅₀	0.04 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 19783447]
MDA-MB-435	GI₅₀	0.04 μM Compound: 1, CPT	Antiproliferative activity against human MDA-MB-435 cells Antiproliferative activity against human MDA-MB-435 cells	[PMID: 20155916]
MDA-MB-435	IC₅₀	0.71 μM Compound: CPT	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 20942490]
MDA-MB-435	GI₅₀	0.033 μM Compound: 1, CPT	Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
MDA-MB-435	IC₅₀	0.0436 μM Compound: CPT	Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 23084702]
MDA-MB-435	IC₅₀	<0.001 μM Compound: 1, CPT	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 24069881]
MDA-MB-435	IC₅₀	1 μM Compound: CPT	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 26226379]
MDA-MB-435	IC₅₀	2.7 μM Compound: CPT	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
MDA-MB-435	IC₅₀	0.31 μM Compound: 1; CPT	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition rate incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition rate incubated for 72 hrs by MTT assay	[PMID: 34844412]
MDA-MB-436	IC₅₀	31.86 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay	[PMID: 31398033]
MDA-MB-453	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human MDA-MB-453 cells after 3 days by SRB assay Cytotoxicity against human MDA-MB-453 cells after 3 days by SRB assay	[PMID: 23142674]
MDA-MB-453	IC₅₀	<0.01 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-453 cells assessed as reduction in cell growth after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-453 cells assessed as reduction in cell growth after 72 hrs by MTT assay	[PMID: 38107170]
MDA-MB-468	IC₅₀	14.76 μM Compound: Camptothecin	Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 26602827]
MDA-MB-468	IC₅₀	1.71 μM Compound: Camptothecin	Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
MDA-MB-468	IC₅₀	>100 μM Compound: CPT	Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
MEF	IC₅₀	5.87 μg/mL Compound: Camptothecin	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 25867737]
MES-SA	IC₅₀	57 nM Compound: 1a	Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay	[PMID: 21341674]
MES-SA/Dx5	IC₅₀	52 nM Compound: 1a	Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay	[PMID: 21341674]
MFE-296	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human MFE296 cells incubated for 72 hrs by SRB assay Cytotoxicity against human MFE296 cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
MG-63	IC₅₀	0.046 μM Compound: CPT	Cytotoxicity against human MG-63 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MG-63 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
MGC-803	IC₅₀	9.45 μM Compound: Camptothecin	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 28462840]
MGC-803	IC₅₀	2.96 μM Compound: CPT	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30685528]
MGC-803	IC₅₀	4.27 μM Compound: CPT	Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30875505]
MGC-803	IC₅₀	>150 μM Compound: CPT	Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
MGC-803	IC₅₀	17.76 μM Compound: Camptothecin	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
MGC-803	IC₅₀	>100 μM Compound: CPT	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
MHCC97H	IC₅₀	0.32 nM Compound: Camptothecin	Cytotoxicity against human MHCC97H cells after 48 hrs by CCK8 assay Cytotoxicity against human MHCC97H cells after 48 hrs by CCK8 assay	[PMID: 30702286]
MIA PaCa-2	IC₅₀	0.4 μM Compound: Camptothecin	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
MIA PaCa-2	IC₅₀	0.19 μM Compound: Camptothecin	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 24041234]
MIA PaCa-2	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
MIA PaCa-2	IC₅₀	0.18 μM Compound: CPT	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs in presence of type 1 collagen coated surface by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs in presence of type 1 collagen coated surface by MTT assay	[PMID: 28689976]
MIA PaCa-2	IC₅₀	0.19 μM Compound: Camptothecin	Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
MKN-45	IC₅₀	17 nM Compound: CPT	In Vitro cytotoxicity against human stomach cancer cell line (MKN45) In Vitro cytotoxicity against human stomach cancer cell line (MKN45)	[PMID: 11334569]
MOLT-4	IC₅₀	0.04 nM Compound: CPT	Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 24900725]
MRC5	IC₅₀	0.89 μM Compound: 4	Antiproliferative activity against human MRC5 cells Antiproliferative activity against human MRC5 cells	[PMID: 21599000]
MRC5	CC₅₀	0.2 μM Compound: Camptothecin	Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay	[PMID: 22047799]
MRC5	CC₅₀	0.2 μM Compound: Camptothecin	Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay	[PMID: 22884523]
MRC5	IC₅₀	1.7 μM Compound: I; CPT	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 32279049]
MRC5	IC₅₀	1.7 x 10^-5 μM Compound: CPT	Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 33962152]
MRC5	IC₅₀	0.8 μM Compound: CPT	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 3 days by resazurin staining based analysis Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 3 days by resazurin staining based analysis	[PMID: 34952177]
MRC5	IC₅₀	9.02 μM Compound: Camptothecin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
MRC5	IC₅₀	>300 μM Compound: CPT	Cytostatic activity against human MRC5 cells after 24 hrs by CCK-8 assay Cytostatic activity against human MRC5 cells after 24 hrs by CCK-8 assay	[PMID: 38278140]
MSTO-211H	GI₅₀	0.0021 μM Compound: CPT	Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay	[PMID: 27597409]
MT4	IC₅₀	0.004 μM Compound: CPT	Antiproliferative activity against human MT4 cells by MTT assay Antiproliferative activity against human MT4 cells by MTT assay	[PMID: 17254669]
MT4	IC₅₀	0.004 μM Compound: Camptothecin	Cytotoxicity against human MT4 cells after 96 hrs Cytotoxicity against human MT4 cells after 96 hrs	[PMID: 22276775]
MT4	CC₅₀	0.004 μM Compound: Camptothecin	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 22884523]
MT4	CC₅₀	0.01 μM Compound: Camptothecin	Compound concentration required to reduce the exponential growth of MT-4 cells by 50% Compound concentration required to reduce the exponential growth of MT-4 cells by 50%	[PMID: 9767632]
MX1	IC₅₀	1700 nM Compound: CPT	Cytotoxicity against human MX1 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MX1 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24901491]
NB-4	IC₅₀	2.01 μM Compound: Camptothecin	Antitumor activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
NCI/ADR-RES	IC₅₀	0.8 μM Compound: camptothecin	Cytotoxicity against human MCF7/ADR cells by WST-1 assay Cytotoxicity against human MCF7/ADR cells by WST-1 assay	[PMID: 22197145]
NCI-H128	IC₅₀	18 nM Compound: CPT	In Vitro cytotoxicity against human lung cancer cell line (H128) In Vitro cytotoxicity against human lung cancer cell line (H128)	[PMID: 11334569]
NCI-H1299	IC₅₀	0.8 μM Compound: Camptothecin	Cytotoxicity against human NCI-H1299 cells by MTT assay Cytotoxicity against human NCI-H1299 cells by MTT assay	[PMID: 28506750]
NCI-H1299	IC₅₀	>100 μM Compound: CPT	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
NCI-H1299	IC₅₀	3.14 μM Compound: CPT	Antiproliferative activity against human H1299 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human H1299 cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
NCI-H1975	IC₅₀	1.2 μM Compound: Camptothecin	Cytotoxicity against human NCI-H1975 cells by MTT assay Cytotoxicity against human NCI-H1975 cells by MTT assay	[PMID: 28506750]
NCI-H23	IC₅₀	0.07 μM Compound: CPT	Cytotoxicity against human NCI-H23 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 27156772]
NCI-H446	IC₅₀	>200 μM Compound: CPT	Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay	[PMID: 26226379]
NCI-H446	IC₅₀	>200 μM Compound: CPT	Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
NCI-H460	IC₅₀	0.33 μM Compound: 1a (Camptothecin)	In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line	[PMID: 11052801]
NCI-H460	EC₅₀	0.0069 μM Compound: camptothecin	Cytotoxicity against human H460 after 3 days by SRB assay Cytotoxicity against human H460 after 3 days by SRB assay	[PMID: 15730238]
NCI-H460	IC₅₀	0.0062 μM Compound: 1, CPT	Cytotoxicity against human H460 cells after 72 hrs Cytotoxicity against human H460 cells after 72 hrs	[PMID: 18419110]
NCI-H460	IC₅₀	0.33 μM Compound: 1, CPT	Cytotoxicity against human H460 cells after 1 hr Cytotoxicity against human H460 cells after 1 hr	[PMID: 18419110]
NCI-H460	IC₅₀	0.18 μM Compound: 1, camptothecin, CPT	Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs	[PMID: 18424133]
NCI-H460	IC₅₀	0.33 μM Compound: 1, CPT	Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium	[PMID: 19530720]
NCI-H460	GI₅₀	0.03 μM Compound: CPT	Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay	[PMID: 20591678]
NCI-H460	IC₅₀	>25 μM Compound: CPT	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 20638158]
NCI-H460	IC₅₀	>1000 nM Compound: 1a	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA	[PMID: 21341674]
NCI-H460	IC₅₀	13 nM Compound: 1a	Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
NCI-H460	IC₅₀	<0.04 μM Compound: Camptothecin	Cytotoxicity against human H460 cells after 72 hrs by MTS assay Cytotoxicity against human H460 cells after 72 hrs by MTS assay	[PMID: 21513293]
NCI-H460	IC₅₀	0.03 μM Compound: 4	Anticancer activity against human NCI-H460 cells Anticancer activity against human NCI-H460 cells	[PMID: 21599000]
NCI-H460	IC₅₀	5 nM Compound: Cpt	Cytotoxicity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay	[PMID: 22749423]
NCI-H460	IC₅₀	0.003 μM Compound: Camptothecin	Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay	[PMID: 22758788]
NCI-H460	IC₅₀	0.002 μM Compound: Camptothecin	Cytotoxicity against human NCI-H460 cells incubated for 3 days by SRB assay Cytotoxicity against human NCI-H460 cells incubated for 3 days by SRB assay	[PMID: 22863526]
NCI-H460	IC₅₀	0.19 μM Compound: CPT	Cytotoxicity against human NCI-H460 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 27156772]
NCI-H460	GI₅₀	0.002 μM Compound: CPT	Growth inhibition of human H460 cells after 72 hrs by trypan blue assay Growth inhibition of human H460 cells after 72 hrs by trypan blue assay	[PMID: 27597409]
NCI-H460	GI₅₀	0.0057 μM Compound: Camptothecin	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
NCI-H460	IC₅₀	110 nM Compound: Camptothecin	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29541373]
NCI-H460	IC₅₀	5.37 μM Compound: CPT	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30875505]
NCI-H460	IC₅₀	0.12 μM Compound: CPT	Cytotoxicity against human NCI-H460 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 32711231]
NCI-H460	IC₅₀	0.79 μM Compound: Camptothecin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36758308]
NCI-H520	IC₅₀	25.01 nM Compound: CPT	Cytotoxicity against human NCI-H520 cells assessed as inhibition of cell growth Cytotoxicity against human NCI-H520 cells assessed as inhibition of cell growth	[PMID: 37806498]
NCI-H69	IC₅₀	1 nM Compound: 1a	Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
NCI-H928	IC₅₀	7.8 nM Compound: 1	Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human lung carcinoma cells (H928) Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human lung carcinoma cells (H928)	[PMID: 10479293]
NCI-N87	IC₅₀	0.6 μM Compound: Camptothecin	Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
NCI-N87	IC₅₀	2.32 μM Compound: CPT	Cytotoxicity against HER-positive human NCI-N87 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against HER-positive human NCI-N87 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36351049]
NCI-N87	IC₅₀	2.07 μM Compound: CPT	Cytotoxicity against HER-positive human NCI-N87 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against HER-positive human NCI-N87 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38104378]
NHDF	IC₅₀	5.38 μM Compound: Camptothecin	Cytotoxicity against HDF cells Cytotoxicity against HDF cells	[PMID: 32932211]
NIH3T3	IC₅₀	12 μM Compound: Camptothecin	Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form	[PMID: 11430001]
NIH3T3	IC₅₀	0.086 μM Compound: CPT	Cytotoxicity against mouse NIH3T3 cells measured after 72 hrs Cytotoxicity against mouse NIH3T3 cells measured after 72 hrs	[PMID: 38716896]
OVCAR-3	GI₅₀	0.22 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line	[PMID: 11020283]
OVCAR-3	GI₅₀	0.22 μM Compound: 2	Growth inhibitory activity against human ovarian OVCAR-3 cell line Growth inhibitory activity against human ovarian OVCAR-3 cell line	[PMID: 15509164]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human OVCAR-3 cell line Antiproliferative activity against human OVCAR-3 cell line	[PMID: 16442283]
OVCAR-3	GI₅₀	0.22 μM Compound: 2	Antiproliferative activity against human OVCAR-3 cell line Antiproliferative activity against human OVCAR-3 cell line	[PMID: 16913702]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 17402722]
OVCAR-3	GI₅₀	0.22 μM Compound: 1, Camptothecin	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 17676830]
OVCAR-3	GI₅₀	0.22 μM Compound: 2	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 17696418]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human OVCAR-3 cells Antiproliferative activity against human OVCAR-3 cells	[PMID: 18630891]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 19783447]
OVCAR-3	GI₅₀	0.22 μM Compound: 1, CPT	Antiproliferative activity against human OVCAR-3 cells Antiproliferative activity against human OVCAR-3 cells	[PMID: 20155916]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Cytotoxicity against human OVCAR-3 cells Cytotoxicity against human OVCAR-3 cells	[PMID: 20630766]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human OVCAR3 cells by SRB assay Antiproliferative activity against human OVCAR3 cells by SRB assay	[PMID: 21710981]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 21823606]
OVCAR-3	GI₅₀	0.22 μM Compound: 2	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Cytotoxicity against human OVCAR3 cells by SRB assay Cytotoxicity against human OVCAR3 cells by SRB assay	[PMID: 24502276]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 24800942]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human OVCAR3 cells after 48 hrs Antiproliferative activity against human OVCAR3 cells after 48 hrs	[PMID: 27070999]
OVCAR-3	GI₅₀	0.22 μM Compound: 18	Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 28418653]
OVCAR-3	GI₅₀	0.22 μM Compound: 1	Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition	[PMID: 28657311]
P388	IC₅₀	0.032 μM Compound: CPT	In vitro inhibitory concentration against murine P388 leukemia cell proliferation In vitro inhibitory concentration against murine P388 leukemia cell proliferation	[PMID: 10346933]
P388	IC₅₀	13 nM Compound: Camptothecin	Inhibitory activity against P388 murine leukemia cells Inhibitory activity against P388 murine leukemia cells	[PMID: 11384245]
P388	IC₅₀	7 nM Compound: Camptothecin	Inhibitory activity against P388 Leukemia cells Inhibitory activity against P388 Leukemia cells	[PMID: 12565975]
P388	IC₅₀	13 nM Compound: Camptothecin	Growth inhibitory activity against murine P388 leukemia cells Growth inhibitory activity against murine P388 leukemia cells	[PMID: 12620081]
P388	IC₅₀	0.01 μM Compound: CPT	Concentration required to inhibit cell proliferation in P388 tumor cell line Concentration required to inhibit cell proliferation in P388 tumor cell line	[PMID: 15482929]
P388	IC₅₀	32.1 nM Compound: camptothecin	Cytotoxicity against mouse P388 cells after 72 hrs Cytotoxicity against mouse P388 cells after 72 hrs	[PMID: 17624792]
P388	IC₅₀	0.004 nM Compound: CPT, campothecin	Cytotoxicity against human P388 cells Cytotoxicity against human P388 cells	[PMID: 18511275]
P388	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay	[PMID: 18676151]
P388	IC₅₀	0.009 μM Compound: CPT	Cytotoxicity against mouse P388 cells after 4 days by MTT assay Cytotoxicity against mouse P388 cells after 4 days by MTT assay	[PMID: 18676151]
P388	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method	[PMID: 18771930]
P388	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against mouse P388 cells by MTT method Cytotoxicity against mouse P388 cells by MTT method	[PMID: 18771930]
P388	IC₅₀	0.014 μM Compound: CPT	Cytotoxicity against mouse P388 cells after MTT assay Cytotoxicity against mouse P388 cells after MTT assay	[PMID: 18829334]
P388	IC₅₀	0.014 μM Compound: CPT	Cytotoxicity against mouse P388 cells by MTT method Cytotoxicity against mouse P388 cells by MTT method	[PMID: 19012996]
P388	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against mouse P388 cells after 4 days by MTT assay Cytotoxicity against mouse P388 cells after 4 days by MTT assay	[PMID: 19299037]
P388	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method	[PMID: 19303306]
P388	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against mouse P388 cells after 4 days by MTT method Cytotoxicity against mouse P388 cells after 4 days by MTT method	[PMID: 19303306]
P388	ED₅₀	8.6 x 10^-6 mM Compound: 1, Camptothecin	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 423214]
P388	IC₅₀	4.74 ng/mL Compound: 1a	Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay	[PMID: 7932525]
P388	IC₅₀	4.74 ng/mL Compound: 1	In vitro antitumor activity against P388 (murine leukemia) cells. In vitro antitumor activity against P388 (murine leukemia) cells.	[PMID: 9632364]
P388	IC₅₀	0.005 μg/mL Compound: Camptothecin (CPT)	Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells	10.1016/S0960-894X(97)00071-1
P388CPT45	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay	[PMID: 18829334]
P388CPT45	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay	[PMID: 19299037]
P388CPT5	IC₅₀	2.8 μM Compound: CPT	In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation	[PMID: 10346933]
PANC-1	GI₅₀	6.29 μM Compound: 1, CPT	Cytotoxicity against human PANC1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PANC1 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
PANC-1	IC₅₀	0.09 μM Compound: CPT	Cytotoxicity against human PANC1 cells after 72 hrs by XTT assay Cytotoxicity against human PANC1 cells after 72 hrs by XTT assay	[PMID: 30017114]
PANC-1	IC₅₀	0.18 μM Compound: CPT	Cytotoxicity against human PANC1 cells after 48 hrs by XTT assay Cytotoxicity against human PANC1 cells after 48 hrs by XTT assay	[PMID: 30017114]
PANC-1	IC₅₀	0.233 μM Compound: CPT	Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
Panel (56 tumour cell lines)	IC₅₀	0.04 μM Compound: 20(S)-Camptothecin	Tested in vitro for cytotoxicity against 56 human tumor cell lines Tested in vitro for cytotoxicity against 56 human tumor cell lines	[PMID: 10714502]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	10 nM Compound: Camptothecin E	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]
PBMC	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
PC-3	IC₅₀	0.31 μM Compound: CPT	In vitro cytotoxic activity of compound against human PC3 cell line In vitro cytotoxic activity of compound against human PC3 cell line	[PMID: 15081041]
PC-3	IC₅₀	1414.4 nM Compound: Camptothecin (table 1)	Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line	[PMID: 15454230]
PC-3	IC₅₀	52 nM Compound: camptothecin	Antiproliferative activity against human PC3 cell line Antiproliferative activity against human PC3 cell line	[PMID: 16686539]
PC-3	ED₅₀	16.7 nM Compound: 3a, CPT, Camptothecin	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 17350834]
PC-3	GI₅₀	0.09 μM Compound: 1, camptothecin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 18180162]
PC-3	GI₅₀	0.7 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay	[PMID: 19715319]
PC-3	IC₅₀	1.4 μM Compound: 1, CPT	Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay	[PMID: 19715319]
PC-3	GI₅₀	0.09 μM Compound: CPT	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20662543]
PC-3	IC₅₀	16.24 μM Compound: CPT	Cytotoxicity against human PC3 after 48 hrs by SRB assay Cytotoxicity against human PC3 after 48 hrs by SRB assay	[PMID: 21044847]
PC-3	IC₅₀	0.03 μM Compound: Camptothecin	Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 21074444]
PC-3	GI₅₀	0.06 μM Compound: Camptothecin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21115210]
PC-3	IC₅₀	12 nM Compound: 1a	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 21341674]
PC-3	GI₅₀	0.48 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21388138]
PC-3	GI₅₀	>287 μM Compound: 1, CPT	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
PC-3	IC₅₀	1.2 μM Compound: Camptothecin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24041234]
PC-3	IC₅₀	0.01 μM Compound: Camptothecin	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 24180210]
PC-3	IC₅₀	78 nM Compound: CPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900725]
PC-3	IC₅₀	0.1 μM Compound: CPT	Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
PC-3	IC₅₀	2.5 μM Compound: CPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26226379]
PC-3	IC₅₀	6.96 μM Compound: Camptothecin	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 29131616]
PC-3	IC₅₀	>40 μM Compound: Camp	Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay	[PMID: 29223099]
PC-3	IC₅₀	0.4 μM Compound: Camp	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
PC-3	IC₅₀	18.24 μM Compound: Camptothecin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30109008]
PC-3	IC₅₀	2.4 μM Compound: CPT	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
PC-3	IC₅₀	>100 μM Compound: CPT	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 37708799]
PC-3	IC₅₀	6.6 μM Compound: CPT	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
PC-3	IC₅₀	0.234 μM Compound: CPT	Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
PC-3	IC₅₀	57 nM Compound: CPT	Antiproliferative activity measured against PC-3 human prostate adenocarcinoma Antiproliferative activity measured against PC-3 human prostate adenocarcinoma	[PMID: 9876111]
PC-3	IC₅₀	1.2 μM Compound: Camptothecin	Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C4MD00344F
PC-3M	IC₅₀	0.19 μM Compound: Camptothecin	Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method	[PMID: 35696646]
PC-3M	IC₅₀	0.48 μM Compound: Camptothecin	Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay	[PMID: 35696646]
QG-56	IC₅₀	4.63 ng/mL Compound: 1a	Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay	[PMID: 7932525]
QG-56	IC₅₀	4.63 ng/mL Compound: 1	In vitro antitumor activity against QG-56 (human lung cancer) cells. In vitro antitumor activity against QG-56 (human lung cancer) cells.	[PMID: 9632364]
Raji	IC₅₀	1 μM Compound: camptothecin	Cytotoxicity against human Raji cells by MTT assay Cytotoxicity against human Raji cells by MTT assay	[PMID: 20329739]
Raji	IC₅₀	3.27 μM Compound: Camptothecin	Cytotoxicity against human Raji cells after 48 hrs by MTT assay Cytotoxicity against human Raji cells after 48 hrs by MTT assay	[PMID: 30109008]
RD	IC₅₀	4.47 μM Compound: Camptothecin	Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay	[PMID: 23974020]
RD	IC₅₀	1.24 μM Compound: CPT	Cytotoxicity against human TE32 cells measured after 72 hrs by MTT assay Cytotoxicity against human TE32 cells measured after 72 hrs by MTT assay	[PMID: 27721148]
RD	IC₅₀	4.49 μM Compound: Camptothecin	Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
RD	IC₅₀	1.24 μM Compound: CPT	Cytotoxicity against human TE32 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human TE32 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28923388]
RD	IC₅₀	1.72 μM Compound: CPT	Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
Renca	IC₅₀	304 nM Compound: camptothecin	Antiproliferative activity against mouse Renca cell line Antiproliferative activity against mouse Renca cell line	[PMID: 16686539]
RKO	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay	[PMID: 35462164]
RKO	IC₅₀	0.0617 μM Compound: CPT	Antiproliferative activity against human RKO cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human RKO cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35868003]
RPMI 8402	IC₅₀	0.005 μM Compound: Camptothecin	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment	[PMID: 12747798]
RPMI 8402	IC₅₀	>10 μM Compound: CPT	Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant	[PMID: 15482929]
RPMI 8402	IC₅₀	0.006 μM Compound: CPT	Concentration required to inhibit cell proliferation in RPM18402 tumor cell line Concentration required to inhibit cell proliferation in RPM18402 tumor cell line	[PMID: 15482929]
RPMI 8402	IC₅₀	0.005 μM Compound: CPT	Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay	[PMID: 18676151]
RPMI 8402	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against human RPMI8402 cells by MTT method Cytotoxicity against human RPMI8402 cells by MTT method	[PMID: 18771930]
RPMI 8402	IC₅₀	0.006 μM Compound: CPT	Cytotoxicity against human RPMI8402 cells after MTT assay Cytotoxicity against human RPMI8402 cells after MTT assay	[PMID: 18829334]
RPMI 8402	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay	[PMID: 19299037]
RPMI 8402	IC₅₀	0.004 μM Compound: CPT	Cytotoxicity against human RPMI8402 cells after 4 days by MTT method Cytotoxicity against human RPMI8402 cells after 4 days by MTT method	[PMID: 19303306]
RPMI-7951	IC₅₀	0.22 μM Compound: CPT	Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
RPMI-8226	IC₅₀	0.006 μM Compound: CPT	Cytotoxicity against human RPMI8226 cells by MTT method Cytotoxicity against human RPMI8226 cells by MTT method	[PMID: 19012996]
RPMI-8226	IC₅₀	2.05 μg/mL Compound: Camptothecin	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 25867737]
SAOS-2	GI₅₀	>287 μM Compound: 1, CPT	Cytotoxicity against human Saos2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human Saos2 cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
SAOS-2	IC₅₀	0.055 μM Compound: CPT	Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
SAS	GI₅₀	6 μM Compound: 1, camptothecin	Antiproliferative activity against human SAS cells after 48 hrs by MTT assay Antiproliferative activity against human SAS cells after 48 hrs by MTT assay	[PMID: 18180162]
SAS	GI₅₀	6 μM Compound: CPT	Cytotoxicity against human SAS cells after 48 hrs by MTT assay Cytotoxicity against human SAS cells after 48 hrs by MTT assay	[PMID: 20662543]
SAS	IC₅₀	6 μM Compound: CPT	Antiproliferative activity against human SAS cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SAS cells incubated for 72 hrs by MTT assay	10.1039/C4MD00133H
SF-268	EC₅₀	0.059 μM Compound: camptothecin	Cytotoxicity against human SF-268 after 3 days by SRB assay Cytotoxicity against human SF-268 after 3 days by SRB assay	[PMID: 15730238]
SF-268	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human SF268 cell line Antiproliferative activity against human SF268 cell line	[PMID: 16442283]
SF-268	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 17402722]
SF-268	GI₅₀	0.19 μM Compound: CPT	Cytotoxicity against human SF268 cells after 72 hrs by XTT assay Cytotoxicity against human SF268 cells after 72 hrs by XTT assay	[PMID: 20591678]
SF-268	IC₅₀	0.04 μM Compound: Camptothecin	Cytotoxicity against human SF268 cells after 72 hrs by MTS assay Cytotoxicity against human SF268 cells after 72 hrs by MTS assay	[PMID: 21513293]
SF-268	IC₅₀	0.19 μM Compound: 4	Anticancer activity against human SF268 cells Anticancer activity against human SF268 cells	[PMID: 21599000]
SF-268	IC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human SF268 cells incubated for 3 days by SRB assay Cytotoxicity against human SF268 cells incubated for 3 days by SRB assay	[PMID: 22863526]
SF-539	GI₅₀	0.01 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line	[PMID: 11020283]
SF-539	GI₅₀	0.01 μM Compound: 2	Antiproliferative activity against human SF539 cell line Antiproliferative activity against human SF539 cell line	[PMID: 16913702]
SF-539	GI₅₀	0.01 μM Compound: 1, Camptothecin	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 17676830]
SF-539	GI₅₀	0.01 μM Compound: 2	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 17696418]
SF-539	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human SF539 cells Antiproliferative activity against human SF539 cells	[PMID: 18630891]
SF-539	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 19783447]
SF-539	GI₅₀	0.01 μM Compound: 1, CPT	Antiproliferative activity against human SF539 cells Antiproliferative activity against human SF539 cells	[PMID: 20155916]
SF-539	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 20630766]
SF-539	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human SF539 cells by SRB assay Antiproliferative activity against human SF539 cells by SRB assay	[PMID: 21710981]
SF-539	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human SF539 cells after 48 hrs by SRB assay Cytotoxicity against human SF539 cells after 48 hrs by SRB assay	[PMID: 21823606]
SF-539	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
SF-539	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human SF539 cells by SRB assay Cytotoxicity against human SF539 cells by SRB assay	[PMID: 24502276]
SF-539	GI₅₀	0.01 μM Compound: 1	Growth inhibition of human SF539 cells after 48 hrs by SRB assay Growth inhibition of human SF539 cells after 48 hrs by SRB assay	[PMID: 24800942]
SF-539	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human SF539 cells after 48 hrs Antiproliferative activity against human SF539 cells after 48 hrs	[PMID: 27070999]
SF-539	GI₅₀	<0.01 μM Compound: 18	Cytotoxicity against human SF539 cells after 48 hrs by SRB assay Cytotoxicity against human SF539 cells after 48 hrs by SRB assay	[PMID: 28418653]
SF-539	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human SF539 cells assessed as growth inhibition Antiproliferative activity against human SF539 cells assessed as growth inhibition	[PMID: 28657311]
Sf9	IC₅₀	0.025 μM Compound: CPT	Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis	[PMID: 30897325]
SGC-7901	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
SGC-7901	IC₅₀	5.8 μM Compound: CPT	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 35868003]
SH-SY5Y	IC₅₀	>100 μM Compound: Camptothecin	Growth inhibition of human SH-SY5Y cells after 72 hrs by MTT assay Growth inhibition of human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 27344492]
SH-SY5Y	IC₅₀	0.61 μM Compound: CPT	Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
SiHa	GI₅₀	0.55 μM Compound: Camptothecin	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human SiHa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
SK-BR-3	IC₅₀	20 nM Compound: CPT	In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3) In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)	[PMID: 11334569]
SK-BR-3	GI₅₀	0.15 μM Compound: Camptothecin	Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 48 hrs by SRB assay Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 48 hrs by SRB assay	[PMID: 20438092]
SK-BR-3	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human SKBR3 cells after 3 days by SRB assay Cytotoxicity against human SKBR3 cells after 3 days by SRB assay	[PMID: 23142674]
SK-BR-3	IC₅₀	0.21 μM Compound: CPT	Cytotoxicity against HER-positive human SK-BR-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against HER-positive human SK-BR-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36351049]
SK-BR-3	IC₅₀	0.38 μM Compound: CPT	Cytotoxicity against HER-positive human SK-BR-3 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against HER-positive human SK-BR-3 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38104378]
SK-BR-3	IC₅₀	<0.01 μM Compound: Camptothecin	Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	[PMID: 38107170]
SK-HEP1	IC₅₀	0.96 μM Compound: CPT	Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay	[PMID: 26226379]
SK-HEP1	IC₅₀	0.9 μM Compound: CPT	Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31880942]
SK-MEL	GI₅₀	0.047 μM Compound: 1	Cytotoxicity against human SK-MEL cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL cells after 72 hrs by MTT assay	[PMID: 21388138]
SK-MEL-2	IC₅₀	0.165 μM Compound: camptothecin	Cytotoxicity against human SK-MEL-2 cells after 48 hrs Cytotoxicity against human SK-MEL-2 cells after 48 hrs	[PMID: 17673337]
SK-MEL-2	IC₅₀	0.075 μM Compound: CPT, campothecin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 17827007]
SK-MEL-2	IC₅₀	6.88 μg/mL Compound: CPT	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 21684168]
SK-MEL-2	IC₅₀	7.86 μM Compound: CPT	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by MTT assay	[PMID: 21873069]
SK-MEL-24	IC₅₀	0.46 μM Compound: CPT	Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32435422]
SK-MEL-28	IC₅₀	0.04 μM Compound: CPT	Antiproliferative activity against human SK-MEL-28 cells by MTT assay Antiproliferative activity against human SK-MEL-28 cells by MTT assay	[PMID: 17254669]
SK-MEL-28	CC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 22047799]
SK-MEL-28	CC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 22884523]
SK-MEL-28	IC₅₀	<0.01 μM Compound: Camptothecin	Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 24180210]
SK-MEL-28	IC₅₀	2.26 μM Compound: CPT	Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
SK-MES-1	IC₅₀	0.01 μM Compound: CPT	Antiproliferative activity against human SKMES1 cells by MTT assay Antiproliferative activity against human SKMES1 cells by MTT assay	[PMID: 17254669]
SK-MES-1	CC₅₀	0.03 μM Compound: Camptothecin	Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 22047799]
SK-MES-1	CC₅₀	0.05 μM Compound: Camptothecin	Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 22884523]
SK-OV-3	IC₅₀	20 nM Compound: CPT	In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3) In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)	[PMID: 11334569]
SK-OV-3	IC₅₀	0.014 μM Compound: camptothecin	Cytotoxicity against human SK-OV3 cells after 48 hrs Cytotoxicity against human SK-OV3 cells after 48 hrs	[PMID: 17673337]
SK-OV-3	IC₅₀	1.54 μg/mL Compound: CPT	Cytotoxicity against human SKOV3 cells by sulforhodamine B assay Cytotoxicity against human SKOV3 cells by sulforhodamine B assay	[PMID: 21684168]
SK-OV-3	IC₅₀	2.544 μM Compound: CPT	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 21873069]
SK-OV-3	IC₅₀	5.5 nM Compound: Camptothecin	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 27017547]
SK-OV-3	IC₅₀	5.5 x 10^-3 μM Compound: Camptothecin	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay	[PMID: 27017547]
SK-OV-3	IC₅₀	5.5 nM Compound: CPT	Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay	[PMID: 29501943]
SK-OV-3	IC₅₀	5.5 x 10^-3 μM Compound: CPT	Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay	[PMID: 29501943]
SK-OV-3	IC₅₀	5.5 nM Compound: I; CPT	Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay	[PMID: 31229877]
SK-OV-3	IC₅₀	5.5 x 10^-3 μM Compound: I; CPT	Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay	[PMID: 31229877]
SK-OV-3	IC₅₀	5.5 μM Compound: I; CPT	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 32279049]
SK-OV-3	IC₅₀	5.5 nM Compound: CPT	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 33962152]
SK-OV-3	IC₅₀	5.5 x 10^-3 μM Compound: CPT	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 33962152]
SK-OV-3	IC₅₀	5.5 nM Compound: CPT	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis	[PMID: 34952177]
SK-OV-3	IC₅₀	3.82 μM Compound: CPT	Cytotoxicity against HER-positive human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against HER-positive human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36351049]
SK-OV-3	IC₅₀	2.56 μM Compound: Camptothecin	Antitumor activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
SK-OV-3	IC₅₀	4.86 μM Compound: Camptothecin	Antitumor activity against taxol-resistant human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against taxol-resistant human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
SK-OV-3	IC₅₀	4.07 μM Compound: CPT	Cytotoxicity against HER-positive human SK-OV-3 cells incubated for 48 hrs by CCK-8 assay Cytotoxicity against HER-positive human SK-OV-3 cells incubated for 48 hrs by CCK-8 assay	[PMID: 38104378]
SK-OV-3	IC₅₀	0.241 μM Compound: CPT	Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay	[PMID: 38185054]
SK-OV-3	IC₅₀	37 nM Compound: 1	Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-OV-3	IC₅₀	0.051 μM Compound: Camptothecin	Inhibitory concentration the viability of SKOV 3 cell population by 50%. Inhibitory concentration the viability of SKOV 3 cell population by 50%.	[PMID: 9003520]
SK-VLB	IC₅₀	41 nM Compound: 1	Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-VLB	IC₅₀	0.053 μM Compound: Camptothecin	Inhibitory concentration that reduced the viability of SKVLB cell population by 50%. Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.	[PMID: 9003520]
SMMC-7721	IC₅₀	0.02 μM Compound: CPT	Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay	[PMID: 21044847]
SMMC-7721	IC₅₀	0.003 μM Compound: camptothecin	Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay	[PMID: 21973054]
SMMC-7721	IC₅₀	1.08 μM Compound: CPT	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 30125725]
SMMC-7721	IC₅₀	0.45 μM Compound: CPT; 1	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30509782]
SMMC-7721	IC₅₀	>10 μM Compound: CPT	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34852457]
SMMC-7721	IC₅₀	3.95 μM Compound: Camptothecin	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth by SRB assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth by SRB assay	[PMID: 38107170]
SN12C	GI₅₀	0.02 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line	[PMID: 11020283]
SN12C	GI₅₀	0.02 μM Compound: 2	Growth inhibitory activity against human renal SN12C cell line Growth inhibitory activity against human renal SN12C cell line	[PMID: 15509164]
SN12C	GI₅₀	0.02 μM Compound: Camptothecin	Concentration required to inhibit the growth of human Renal SN12C cells Concentration required to inhibit the growth of human Renal SN12C cells	[PMID: 16033260]
SN12C	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human SN12C cell line Antiproliferative activity against human SN12C cell line	[PMID: 16442283]
SN12C	GI₅₀	0.02 μM Compound: 2	Antiproliferative activity against human SN12C cell line Antiproliferative activity against human SN12C cell line	[PMID: 16913702]
SN12C	GI₅₀	0.02 μM Compound: 1	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 17402722]
SN12C	GI₅₀	0.02 μM Compound: 1, Camptothecin	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 17676830]
SN12C	GI₅₀	0.02 μM Compound: 2	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 17696418]
SN12C	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human SN12C cells Antiproliferative activity against human SN12C cells	[PMID: 18630891]
SN12C	GI₅₀	0.02 μM Compound: 1	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 19783447]
SN12C	GI₅₀	0.02 μM Compound: 1, CPT	Antiproliferative activity against human SN12C cells Antiproliferative activity against human SN12C cells	[PMID: 20155916]
SN12C	GI₅₀	0.02 μM Compound: 1	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 20630766]
SN12C	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human SN12C cells by SRB assay Antiproliferative activity against human SN12C cells by SRB assay	[PMID: 21710981]
SN12C	GI₅₀	0.02 μM Compound: 1	Cytotoxicity against human SN12C cells after 48 hrs by SRB assay Cytotoxicity against human SN12C cells after 48 hrs by SRB assay	[PMID: 21823606]
SN12C	GI₅₀	0.02 μM Compound: 2	Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
SN12C	GI₅₀	0.02 μM Compound: 1	Cytotoxicity against human SN12C cells by SRB assay Cytotoxicity against human SN12C cells by SRB assay	[PMID: 24502276]
SN12C	GI₅₀	0.02 μM Compound: 1	Growth inhibition of human SN12C cells after 48 hrs by SRB assay Growth inhibition of human SN12C cells after 48 hrs by SRB assay	[PMID: 24800942]
SN12C	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human SN12C cells after 48 hrs Antiproliferative activity against human SN12C cells after 48 hrs	[PMID: 27070999]
SN12C	GI₅₀	0.02 μM Compound: 18	Cytotoxicity against human SN12C cells after 48 hrs by SRB assay Cytotoxicity against human SN12C cells after 48 hrs by SRB assay	[PMID: 28418653]
SN12C	GI₅₀	0.02 μM Compound: 1	Antiproliferative activity against human SN12C cells assessed as growth inhibition Antiproliferative activity against human SN12C cells assessed as growth inhibition	[PMID: 28657311]
SNU-475	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
SNU-638	IC₅₀	0.098 μM Compound: camptothecin	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 17498951]
SNU-638	IC₅₀	0.098 μM Compound: 1, CPT	Cytotoxicity against human SNU638 cells Cytotoxicity against human SNU638 cells	[PMID: 21095131]
SNU-638	IC₅₀	0.098 μM Compound: CPT	Cytotoxicity against human SNU638 cells by MTT assay Cytotoxicity against human SNU638 cells by MTT assay	[PMID: 21353568]
SNU-638	IC₅₀	0.28 μM Compound: Camptothecin	Cytotoxicity against human SNU638 cells by MTT assay Cytotoxicity against human SNU638 cells by MTT assay	[PMID: 23608763]
Splenocyte	CC₅₀	0.62 μM Compound: CPT	Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 27639365]
SU-DHL-2	IC₅₀	0.94 μM Compound: Camptothecin	Antitumor activity against human SUDHL2 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human SUDHL2 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
SW1573	GI₅₀	0.21 μM Compound: CPT	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
SW1573	GI₅₀	0.25 μM Compound: Camptothecin	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 23831507]
SW1573	GI₅₀	0.3 μM Compound: Camptothecin	Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
SW1990	IC₅₀	0.2 μM Compound: CPT	Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 32668379]
SW480	IC₅₀	0.29 μM Compound: CPT; 1	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	[PMID: 30509782]
SW480	IC₅₀	0.21 μM Compound: Camptothecin	Antiproliferation activity against human SW480 cells assessed as reduction in cell viability measured after 72 hours by MTT assay Antiproliferation activity against human SW480 cells assessed as reduction in cell viability measured after 72 hours by MTT assay	[PMID: 32201190]
SW480	IC₅₀	8.56 μM Compound: CPT	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38128233]
SW480	IC₅₀	3.75 μM Compound: Camptothecin	Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells	10.1007/s00044-009-9233-5
SW480	IC₅₀	0.01 μg/mL Compound: 1	Cytotoxicity in SW480 cancer cell line Cytotoxicity in SW480 cancer cell line	10.1016/S0960-894X(01)80158-X
SW-620	EC₅₀	0.15 nM Compound: Camptothecin	Concentration required to inhibit growth of SW620 (human colon cancer) cells in the presence of 10 uM of Compound 2e Concentration required to inhibit growth of SW620 (human colon cancer) cells in the presence of 10 uM of Compound 2e	[PMID: 15857116]
SW-620	EC₅₀	1.2 nM Compound: Camptothecin	Concentration required to inhibit growth of SW620 (human colon cancer) cells Concentration required to inhibit growth of SW620 (human colon cancer) cells	[PMID: 15857116]
SW-620	EC₅₀	0.0021 μM Compound: Cpt, camptothecin	Antiproliferative activity against human SW620 cells by soft agar assay Antiproliferative activity against human SW620 cells by soft agar assay	[PMID: 17287122]
SW626	IC₅₀	28.7 nM Compound: Camptothecin	Cytotoxicity against human SW626 cells by MTT assay Cytotoxicity against human SW626 cells by MTT assay	[PMID: 11858760]
SW948	IC₅₀	0.16 μM Compound: CPT	Antiproliferative activity against human SW948 cells after 3 days by XTT assay Antiproliferative activity against human SW948 cells after 3 days by XTT assay	[PMID: 19691293]
T-24	IC₅₀	88 nM Compound: CPT	Cytotoxicity against T24 tumor cell line determined by WST-1 assay Cytotoxicity against T24 tumor cell line determined by WST-1 assay	[PMID: 10841808]
T-24	IC₅₀	0.006 μM Compound: camptothecin	Growth inhibition of human T24 cells by neutral red assay Growth inhibition of human T24 cells by neutral red assay	[PMID: 17204425]
T-24	IC₅₀	88 nM Compound: 1, CPT, NSC-100880	Cytotoxicity against human chemo-resistant T24 cells by WST assay Cytotoxicity against human chemo-resistant T24 cells by WST assay	[PMID: 23578545]
T-24	IC₅₀	6.8 μM Compound: CPT	Antiproliferative activity against human T24 cells after 48 hrs by MTT assay Antiproliferative activity against human T24 cells after 48 hrs by MTT assay	[PMID: 30685528]
T-24	IC₅₀	3.09 μM Compound: CPT	Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30875505]
T47D	GI₅₀	1.9 μM Compound: CPT	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
T47D	GI₅₀	2 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells expressing estrogen receptor after 48 hrs by SRB assay Antiproliferative activity against human T47D cells expressing estrogen receptor after 48 hrs by SRB assay	[PMID: 20438092]
T47D	IC₅₀	1.53 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
T47D	IC₅₀	9.17 μM Compound: CPT	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 22819942]
T47D	IC₅₀	<1 μM Compound: CPT	Cytotoxicity against human T47D cells incubated for 72 hrs by SRB assay Cytotoxicity against human T47D cells incubated for 72 hrs by SRB assay	[PMID: 22867707]
T47D	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human T47D cells after 3 days by SRB assay Cytotoxicity against human T47D cells after 3 days by SRB assay	[PMID: 23142674]
T47D	IC₅₀	0.07 μM Compound: Camptothecin	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 23608763]
T47D	GI₅₀	2 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 23831507]
T47D	IC₅₀	0.3 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 2 days by CCK-8 assay Cytotoxicity against human T47D cells after 2 days by CCK-8 assay	[PMID: 24013413]
T47D	IC₅₀	0.28 μM Compound: CPT	Cytotoxicity against human T47D cells after 2 days Cytotoxicity against human T47D cells after 2 days	[PMID: 24904965]
T47D	IC₅₀	0.75 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 4 days by CCK-8 assay Cytotoxicity against human T47D cells after 4 days by CCK-8 assay	[PMID: 25062006]
T47D	IC₅₀	1.84 μM Compound: camptothecin	Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay	[PMID: 25936262]
T47D	IC₅₀	0.31 μM Compound: Camptothecin	Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay	[PMID: 26022080]
T47D	IC₅₀	1.62 μM Compound: CPT	Cytotoxicity against human T47D cells measured after 2 days by MTT assay Cytotoxicity against human T47D cells measured after 2 days by MTT assay	[PMID: 26334499]
T47D	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 2 days by CCK8 assay Cytotoxicity against human T47D cells after 2 days by CCK8 assay	[PMID: 26361737]
T47D	IC₅₀	11.17 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 3 days by CCK8 assay Cytotoxicity against human T47D cells after 3 days by CCK8 assay	[PMID: 26927425]
T47D	IC₅₀	1.84 μM Compound: Camptothecin	Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay	[PMID: 26945111]
T47D	IC₅₀	4.1 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 26988802]
T47D	IC₅₀	0.08 μM Compound: Camptothecin	Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay	[PMID: 27484510]
T47D	IC₅₀	13.7 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 27643560]
T47D	IC₅₀	0.59 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay	[PMID: 27654394]
T47D	IC₅₀	3.67 μM Compound: Camptothecin	Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay	[PMID: 27707625]
T47D	IC₅₀	2.1 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28068603]
T47D	IC₅₀	2.1 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28384547]
T47D	IC₅₀	2.31 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay	[PMID: 28633898]
T47D	IC₅₀	0.07 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay	[PMID: 29402741]
T47D	IC₅₀	0.49 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay	[PMID: 29510948]
T47D	IC₅₀	0.07 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay	[PMID: 30262132]
T47D	IC₅₀	0.25 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay	[PMID: 31398033]
T47D	IC₅₀	0.09 μM Compound: CPT	Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay	[PMID: 34678573]
T47D	GI₅₀	2 μM Compound: Camptothecin	Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
T47D	IC₅₀	207 nM Compound: 1	Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay	[PMID: 7853331]
TERT-RPE1	ED₅₀	230 nM Compound: camptothecin	Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells	[PMID: 15043407]
TERT-RPE1	IC₅₀	>40 μM Compound: Camp	Cytotoxicity against human RPE1 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay Cytotoxicity against human RPE1 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay	[PMID: 29223099]
TERT-RPE1	IC₅₀	27.2 μM Compound: Camp	Induction of apoptosis in human RPE1 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay Induction of apoptosis in human RPE1 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay	[PMID: 29223099]
THP-1	IC₅₀	0.6 μM Compound: 1, CPT	Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
THP-1	EC₅₀	0.16 μM Compound: camptothecin	Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method	[PMID: 20192247]
THP-1	IC₅₀	0.071 μM Compound: Camptothecin	Cytotoxicity against human THP1 cells after 2 days by MTT assay Cytotoxicity against human THP1 cells after 2 days by MTT assay	[PMID: 22325897]
THP-1	IC₅₀	1.89 μM Compound: Camptothecin	Antitumor activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
Tumor Cell line	GI₅₀	44 nM Compound: camptothecin	Mean GI50 against variety of human tumor cell lines Mean GI50 against variety of human tumor cell lines	[PMID: 11052802]
U-251	GI₅₀	0.01 μM Compound: Camptothecin	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay	[PMID: 29313676]
U2OS	GI₅₀	>287 μM Compound: 1, CPT	Cytotoxicity against human U2OS cells incubated for 72 hrs by MTT assay Cytotoxicity against human U2OS cells incubated for 72 hrs by MTT assay	[PMID: 22867019]
U-373MG ATCC	GI₅₀	0.033 μM Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21388138]
U-373MG ATCC	IC₅₀	0.015 μM Compound: Camptothecin	Growth inhibition of human U373 cells after 72 hrs by MTT assay Growth inhibition of human U373 cells after 72 hrs by MTT assay	[PMID: 24180210]
U-87MG ATCC	IC₅₀	0.5 μM Compound: Camptothecin	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 21186067]
U-87MG ATCC	IC₅₀	0.25 μM Compound: 21	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability	[PMID: 32858470]
U-87MG ATCC	IC₅₀	<1.85 μM Compound: CPT	Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay	[PMID: 35462164]
U-937	IC₅₀	0.015 μM Compound: camptothecin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	0.032 μM Compound: camptothecin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	0.68 μM Compound: camptothecin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	0.3 μM Compound: 1, CPT	Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay	[PMID: 19715319]
U-937	IC₅₀	1.98 μM Compound: Camptothecin	Cytotoxicity against human U937 cells after 2 days by MTT assay Cytotoxicity against human U937 cells after 2 days by MTT assay	[PMID: 22325897]
U-937	IC₅₀	1.81 μM Compound: Camptothecin	Antitumor activity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs Antitumor activity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs	[PMID: 36906964]
U-937	IC₅₀	18.24 μM Compound: Camptothecin	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36996717]
UACC-62	GI₅₀	0.01 μM Compound: 2 (Camptothecin)	Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line	[PMID: 11020283]
UACC-62	GI₅₀	0.01 μM Compound: 2	Growth inhibitory activity against human melanoma UACC-62 cell line Growth inhibitory activity against human melanoma UACC-62 cell line	[PMID: 15509164]
UACC-62	GI₅₀	0.01 μM Compound: Camptothecin	Concentration required to inhibit the growth of human Melanoma UACC-62 cells Concentration required to inhibit the growth of human Melanoma UACC-62 cells	[PMID: 16033260]
UACC-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human UACC62 cell line Antiproliferative activity against human UACC62 cell line	[PMID: 16442283]
UACC-62	GI₅₀	0.01 μM Compound: 2	Antiproliferative activity against human UACC62 cell line Antiproliferative activity against human UACC62 cell line	[PMID: 16913702]
UACC-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 17402722]
UACC-62	GI₅₀	0.01 μM Compound: 1, Camptothecin	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 17676830]
UACC-62	GI₅₀	0.01 μM Compound: 2	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 17696418]
UACC-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human UACC62 cells Antiproliferative activity against human UACC62 cells	[PMID: 18630891]
UACC-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 19783447]
UACC-62	GI₅₀	0.01 μM Compound: 1, CPT	Antiproliferative activity against human UACC62 cells Antiproliferative activity against human UACC62 cells	[PMID: 20155916]
UACC-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 20630766]
UACC-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human UACC62 cells by SRB assay Antiproliferative activity against human UACC62 cells by SRB assay	[PMID: 21710981]
UACC-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 21823606]
UACC-62	GI₅₀	0.01 μM Compound: 2	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 22329436]
UACC-62	GI₅₀	0.01 μM Compound: 1	Cytotoxicity against human UACC62 cells by SRB assay Cytotoxicity against human UACC62 cells by SRB assay	[PMID: 24502276]
UACC-62	GI₅₀	0.01 μM Compound: 1	Growth inhibition of human UACC62 cells after 48 hrs by SRB assay Growth inhibition of human UACC62 cells after 48 hrs by SRB assay	[PMID: 24800942]
UACC-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human UACC62 cells after 48 hrs Antiproliferative activity against human UACC62 cells after 48 hrs	[PMID: 27070999]
UACC-62	GI₅₀	<0.01 μM Compound: 18	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 28418653]
UACC-62	GI₅₀	0.01 μM Compound: 1	Antiproliferative activity against human UACC62 cells assessed as growth inhibition Antiproliferative activity against human UACC62 cells assessed as growth inhibition	[PMID: 28657311]
Vero	IC₅₀	27 μM Compound: Camptothecin	Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form	[PMID: 11430001]
Vero	IC₅₀	0.6 μg/mL Compound: Camptothecin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 21985060]
Vero	IC₅₀	0.02 μg/mL Compound: camptothecin	Cytotoxicity against african green monkey Vero cells after 7 days by XTT assay Cytotoxicity against african green monkey Vero cells after 7 days by XTT assay	[PMID: 8021652]
Vero	IC₅₀	0.054 μg/mL Compound: camptothecin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 8254347]
Vero	IC₅₀	0.054 μg/mL Compound: camptothecin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 9514005]
Vero	IC₅₀	58 μg/mL Compound: Camptothecin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by MTT assay	10.1007/s00044-010-9381-7
WI-38	IC₅₀	0.4 μg/mL Compound: Camptothecin	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 23816880]
WI-38	IC₅₀	0.03 μg/mL Compound: camptothecin	Cytotoxicity against human WI38 cells assessed as cell viability by WST-1 assay Cytotoxicity against human WI38 cells assessed as cell viability by WST-1 assay	[PMID: 24593048]
WI-38	IC₅₀	786 nM Compound: CPT	Cytotoxicity against human WI38 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human WI38 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24901491]
WI-38	IC₅₀	0.23 μM Compound: Campthotecin	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 26063305]
WI-38	IC₅₀	0.03 μM Compound: Camptothecin	Cytotoxicity against human WI38 cells after 48 hrs by WST-1 assay Cytotoxicity against human WI38 cells after 48 hrs by WST-1 assay	[PMID: 28557449]
WI-38	IC₅₀	8.37 μM Compound: CPT	Antiproliferative activity against human WI38 cells after 48 hrs by MTT assay Antiproliferative activity against human WI38 cells after 48 hrs by MTT assay	[PMID: 30685528]
WiDr	IC₅₀	17 nM Compound: CPT	In Vitro cytotoxicity against human colon cancer cell line (WiDr) In Vitro cytotoxicity against human colon cancer cell line (WiDr)	[PMID: 11334569]
WiDr	ED₅₀	0.07 μg/mL Compound: Camptothecin	Cytotoxicity against human WiDr cells by MTT assay Cytotoxicity against human WiDr cells by MTT assay	[PMID: 18220355]
WiDr	IC₅₀	0.07 μg/mL Compound: camptothecin	Cytotoxicity against human WiDr cells by MTT assay Cytotoxicity against human WiDr cells by MTT assay	[PMID: 18774864]
WiDr	GI₅₀	1.7 μM Compound: CPT	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 19664930]
WiDr	GI₅₀	1.8 μM Compound: Camptothecin	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	[PMID: 23831507]
WIL2-NS	IC₅₀	0.005 μM Compound: CPT	Antiproliferative activity against human WIL-2NS cells by MTT assay Antiproliferative activity against human WIL-2NS cells by MTT assay	[PMID: 17254669]
WIL2-NS	CC₅₀	0.005 μM Compound: Camptothecin	Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 22047799]
WIL2-NS	CC₅₀	0.005 μM Compound: Camptothecin	Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 22884523]
ZR-75-1	IC₅₀	<0.01 μM Compound: CPT	Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 23142674]
ZR-75-30	IC₅₀	0.24 μM Compound: CPT	Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay	[PMID: 28351590]

In Vitro

High TOP1 enzymatic activity MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) show high sensitivity toward Camptothecin (0.1 μM to 5 μM; 72 hours) treatment, exhibiting the IC₅₀ values of 0.089 μM and 0.067 μM, respectively^[4].
Camptothecin (0.5 μM; 6 and 24 hours) reduces desferrioxamine-activated VEGF expression.
Camptothecin (0.5 μM; 8 to 24 hours) strongly prevents the desferrioxamine-dependent HIF-1a accumulation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

MCF7 (Luminal subtype) and HCC1419 (HER2 subtype)
Concentration:

0.1 μM to 5 μM
Incubation Time:

72 hours
Result:

High TOP1 enzymatic activity MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) show high sensitivity toward CPT (0.1 μM to 5 μM; 72 hours) treatment, exhibiting the IC₅₀ values of 0.089 μM and 0.067 μM, respectively.

RT-PCR^[2]

Cell Line:

HeLa and HEK293 cell lines
Concentration:

0.5 μmol/L
Incubation Time:

6 and 24 hours
Result:

Reduces desferrioxamine-activated VEGF expression in both cell lines after 6 and 24 hours of treatment, whereas in normoxic condition camptothecin does not affect the VEGF mRNA level.

Western Blot Analysis^[2]

Cell Line:

HeLa and HEK293 cell lines
Concentration:

0.5 μmol/L
Incubation Time:

8 to 24 hours
Result:

Strongly prevents the desferrioxamine-dependent HIF-1a accumulation after 8 to 24 hours, whereas it does not affect HIF-1b levels.

In Vivo

Camptothecin (2 mg/kg every other day) treats mice, has developed numerous pulmonary metastases.
Treatment with both kinase inhibitor of nuclear factor-kappaB-1 (KINK-1) and Camptothecin led to a statistically significant reduction in the number of pulmonary metastases^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL6 mice (injected with B16F10 melanoma cells)^[5]
Dosage:

2 mg/kg
Administration:

every other day, after 19 days
Result:

Has developed numerous pulmonary metastases.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 7689-03-4
Appearance Solid
Molecular Weight 348.35
Formel C₂₀H₁₆N₂O₄
Color Light yellow to yellow
SMILES

O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5
Synonyms

Campathecin; (S)-(+)-Camptothecin; CPT
Structure Classification
- Alkaloids
- Quinoline Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (70)

All WBIFIPCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cancer Cell

Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. [Abstract]

2025 Feb 10;43(2):269-291.e19. PMID: 39933899
Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Mol Cancer

ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma. [Abstract]

2025 Oct 21;24(1):263. PMID: 41121283
Immunity

Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. [Abstract]

2022 Aug 9;55(8):1370-1385.e8. PMID: 35835107
Nat Immunol

A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. [Abstract]

2024 Apr;25(4):659-670. PMID: 38499799
Cancer Res

SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]

2025 May 14. PMID: 40366633
Autophagy

CGAS is a micronucleophagy receptor for the clearance of micronuclei. [Abstract]

2021 Dec;17(12):3976-3991. PMID: 33752561
Nat Commun

Oxidative phosphorylation is a key feature of neonatal monocyte immunometabolism promoting myeloid differentiation after birth. [Abstract]

2025 Mar 6;16(1):2239. PMID: 40050264
Nat Commun

Creating a bacterium that forms eukaryotic nucleosome core particles. [Abstract]

2024 Sep 27;15(1):8283. PMID: 39333491
Nat Commun

Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes. [Abstract]

2022 Aug 16;13(1):4822. PMID: 35973990
Nat Commun

Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. [Abstract]

2021 Aug 16;12(1):4961. PMID: 34400640
Nat Commun

Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]

2019 Aug 21;10(1):3761. PMID: 31434880

Camptothecin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]

Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.
Nat Commun

ATR/Chk1 signaling induces autophagy through sumoylated RhoB-mediated lysosomal translocation of TSC2 after DNA damage. [Abstract]

2018 Oct 8;9(1):4139. PMID: 30297842

Camptothecin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]

One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.
ACS Nano

Coassembly Nanomedicine Mediated by Intermolecular Interactions Between Methotrexate and Baricitinib for Improved Rheumatoid Arthritis Treatment. [Abstract]

2024 Mar 19;18(11):8337-8349. PMID: 38437640
Mol Cell

Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]

2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721
Gene Dis

Ubiquitination status does not affect Vps34 degradation. [Abstract]

2019 May 25;7(3):401-407. PMID: 32884994
Adv Sci (Weinh)

Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System. [Abstract]

2026 Apr;13(23):e11485. PMID: 41671402
Cell Death Differ

TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. [Abstract]

2025 Jul;32(7):1317-1335. PMID: 40133668
Cell Death Differ

Angiopoietin-like protein 8 directs DNA damage responses towards apoptosis by stabilizing PARP1-DNA condensates. [Abstract]

2025 Apr;32(4):672-688. PMID: 39592710
Cell Death Differ

RBMX is required for activation of ATR on repetitive DNAs to maintain genome stability. [Abstract]

2020 Nov;27(11):3162-3176. PMID: 32494026

Camptothecin purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2020 Nov;27(11):3162-3176. [Abstract]

293T cells transfected with Flag-TopBP1 and GFP-tagged RBMX and its domain (RRM, RBM1CTR, and C-RBD) are treated with 100 nM CPT for 24 h and subjected to immunoprecipitation with Flag-beads. Immunoprecipitates are immunoblotted with Flag and GFP antibodies, respectively.
Cancer Lett

ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. [Abstract]

2022 Oct 28:547:215855. PMID: 35998796
Int J Biol Sci

Proton-sensing GPCR-YAP Signalling Promotes Cell Proliferation and Survival. [Abstract]

2015 Aug 8;11(10):1181-9. PMID: 26327812
J Transl Med

Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. [Abstract]

2016 Mar 15:14:73. PMID: 26980293
Proc Natl Acad Sci U S A

The RPA-RNF20-SNF2H cascade promotes proper chromosome segregation and homologous recombination repair. [Abstract]

2023 May 16;120(20):e2303479120. PMID: 37155876
Oncogene

BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. [Abstract]

2023 Mar;42(13):967-979. PMID: 36725890
Int J Mol Med

Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage. [Abstract]

2019 Jun;43(6):2491-2498. PMID: 31017265
Cell Rep

53BP1 regulates p53-E2F7-dependent transcriptional gene repression and participates in the Fanconi anemia pathway. [Abstract]

2025 Aug 12;44(8):116152. PMID: 40811062
Cell Rep

The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability. [Abstract]

2024 Feb 13;43(2):113779. PMID: 38358891
J Med Chem

Modular Synthesis of Bioactive Selenoheterocycles for Efficient Cancer Therapy via Electrochemical Selenylation/Cyclization. [Abstract]

2025 Mar 27;68(6):6339-6360. PMID: 40063343
PLoS Biol

Camptothecin effectively treats obesity in mice through GDF15 induction. [Abstract]

2022 Feb 24;20(2):e3001517. PMID: 35202387
J Cell Biol

lncRNA EGFR-AS1 promotes DNA damage repair by enhancing PARP1-mediated PARylation. [Abstract]

2026 Jan 5;225(1):e202501091. PMID: 41335120
Cells

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. [Abstract]

2019 Oct 15;8(10):1258. PMID: 31619012
Eur J Pharmacol

Targeting Skp2 by camptothecin induces p27 accumulation and confers drug resistance in non-small cell lung cancer. [Abstract]

2026 Jan 12:1011:178422. PMID: 41344534
Front Endocrinol

Cell-Free Fat Extract Improves Ovarian Function and Fertility in Mice With Advanced Age. [Abstract]

2022 Jun 16:13:912648. PMID: 35784529
Stem Cell Reports

KDM8 acts as a co-regulator of transcription factor SOX2 for promoting cell pluripotency. [Abstract]

2026 Jul 14;21(7):102963. PMID: 42314671
Int Immunopharmacol

Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms. [Abstract]

2026 Jan 31:173:116284. PMID: 41621382
Int J Mol Sci

Novel Camptothecin Derivative 9c with Enhanced Antitumor Activity via NSA2-EGFR-P53 Signaling Pathway. [Abstract]

2025 Feb 25;26(5):1987. PMID: 40076615
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Transl Oncol

FOSL1 promotes homologous recombination repair and camptothecin resistance via TCOF1-mediated ribosome biogenesis in non-small cell lung cancer. [Abstract]

2026 Apr:66:102701. PMID: 41687404
Cancers (Basel)

In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]

2023 Sep 6;15(18):4442. PMID: 37760412
J Inflamm Res

FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression. [Abstract]

2025 Mar 20:18:4213-4231. PMID: 40129872
FASEB J

Targeting EME1 Increases the Sensitivity of Camptothecin in Nasopharyngeal Carcinoma Cells. [Abstract]

2026 Jan 31;40(2):e71434. PMID: 41532283
FEBS J

PICH facilitates iPSC reprogramming by alleviating genomic instability induced by DNA replication stress. [Abstract]

2026 Apr 14. PMID: 41981724
BMC Cancer

The Hippo pathway promotes platinum-based chemotherapy by inhibiting MTF1-dependent heavy metal response. [Abstract]

2025 Feb 8;25(1):223. PMID: 39920630
BMC Cancer

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression. [Abstract]

2024 Mar 9;24(1):326. PMID: 38461240
J Cell Physiol

Genistein-induced DNA damage is repaired by nonhomologous end joining and homologous recombination in TK6 cells. [Abstract]

2019 Mar;234(3):2683-2692. PMID: 30070703
PLoS Genet

Strand break-induced replication fork collapse leads to C-circles, C-overhangs and telomeric recombination. [Abstract]

2019 Feb 4;15(2):e1007925. PMID: 30716077
Exp Cell Res

Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma. [Abstract]

2020 Sep 15;394(2):112148. PMID: 32585151
Cell Biol Int

Critical roles of tyrosyl-DNA phosphodiesterases in cell tolerance to carnosol-induced DNA damage. [Abstract]

2020 Aug;44(8):1640-1650. PMID: 32301547
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Toxicol In Vitro

Nonhomologous end joining and homologous recombination involved in luteolin-induced DNA damage in DT40 cells. [Abstract]

2020 Jun;65:104825. PMID: 32169435
Toxicol In Vitro

Multiple repair pathways mediate cellular tolerance to resveratrol-induced DNA damage. [Abstract]

2017 Aug:42:130-138. PMID: 28431926
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
J Hum Genet

Homozygous synonymous FAM111A variant underlies an autosomal recessive form of Kenny-Caffey syndrome. [Abstract]

2025 Feb;70(2):87-97. PMID: 39501122
Exp Ther Med

Critical roles of Rad54 in tolerance to apigenin-induced Top1-mediated DNA damage. [Abstract]

2021 May;21(5):505. PMID: 33791014
Biomed Chromatogr

Quantitative Analysis of the Active Metabolite of VX-150 Using UPLC-MS/MS: A Preclinical Pharmacokinetic Study in Rats. [Abstract]

2025 Nov;39(11):e70237. PMID: 41084234
Biosci Biotechnol Biochem

The fission yeast bromodomain protein Bdf2 is required for the growth of cells with circular chromosomes. [Abstract]

2022 Jan 24;86(2):224-230. PMID: 34918022
bioRxiv

2025 Sep 21.
bioRxiv

2025 Aug 06.
bioRxiv

2025 Aug 19.
SSRN

2025 Jul 26.
bioRxiv

The TONSL-MMS22L complex and FANCM form an interdependent complex on chromatin to counter replication stress. [Abstract]

2025 Mar 10:2025.03.07.642025. PMID: 41030968
bioRxiv

The fate of pyruvate dictates cell growth by modulating cellular redox potential. [Abstract]

2024 Sep 24:2024.09.23.614588. PMID: 39386652
bioRxiv

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. [Abstract]

2023 Sep 28:2023.09.28.559973. PMID: 37808840
Arch Cancer Res

2023 Jan 30.

Camptothecin purchased from MedChemExpress. Usage Cited in: Arch Cancer Res. 2023 Jan 30.

Camptothecin (CPT; 10^-5 -10^-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC₅₀ = 25.36 nM) in U937 cells.
bioRxiv

January 25, 2022.
Health Science Journal

August 31, 2021.
Patent

US20210009719A1.
bioRxiv

2019 Apr.

Lösungsmittel & Löslichkeit

In Vitro:

1M NaOH : 10 mg/mL (28.71 mM; ultrasonic and adjust pH to 11 with NaOH)

DMSO : 6.25 mg/mL (17.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8707 mL

14.3534 mL

28.7068 mL

5 mM

0.5741 mL

2.8707 mL

5.7414 mL

10 mM

0.2871 mL

1.4353 mL

2.8707 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 10 mg/mL (28.71 mM); Suspended solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Luzzio MJ, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. [Content Brief]

[2]. Bertozzi D, et al. The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther. 2014;13(1):239-248. [Content Brief]

[3]. Huang Q, et al. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. Eur J Med Chem. 2013;63:746-757. [Content Brief]

[4]. Tesauro C, et al. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. BMC Cancer. 2019;19(1):1158. Published 2019 Nov 29. [Content Brief]

[5]. Schön M, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst. 2008;100(12):862-875.. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / 1M NaOH	1 mM	2.8707 mL	14.3534 mL	28.7068 mL	71.7669 mL
	5 mM	0.5741 mL	2.8707 mL	5.7414 mL	14.3534 mL
	10 mM	0.2871 mL	1.4353 mL	2.8707 mL	7.1767 mL
	15 mM	0.1914 mL	0.9569 mL	1.9138 mL	4.7845 mL
1M NaOH	20 mM	0.1435 mL	0.7177 mL	1.4353 mL	3.5883 mL
1M NaOH	25 mM	0.1148 mL	0.5741 mL	1.1483 mL	2.8707 mL

Camptothecin

70 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Camptothecin

Toxins for Antibody-Drug Conjugate Research Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

NMPA-Approved Drug Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Chemotherapy Drug Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Camptothecin

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Alle ADC Payloads Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (70)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Camptothecin Related Classifications

HY-16560 Related Classifications